Development of new in vitro models based on the use of electrospun scaffolds and their imaging by multiphoton microscopy coupled with fluorescence lifetime imaging microscopy by Piccirillo, Germano Pasquale
UNIVERSITÀ DEGLI STUDI DI SALERNO 








TESI DI DOTTORATO 
IN  
CHIMICA (XXX CICLO) 
 
Development of new in vitro models based on the 
use of electrospun scaffolds and their imaging by 
multiphoton microscopy coupled with fluorescence 
lifetime imaging microscopy 
 
 
  Relatore:      Candidato: 
  Ch.ma Prof.     Germano Pasquale 
  Brigida BOCHICCHIO   PICCIRILLO 
                                                                  
           Correlatore:                                                    Matr.: 8800100001 
                Ch.ma Prof.      








LIST OF ABBREVIATIONS .................................................................................................. 1 
GENERAL INTRODUCTION ............................................................................................... 4  
OUTLINE AND OBJECTIVES .............................................................................................. 8 
CHAPTER 1. MATERIALS AND METHODS .................................................................. 10 
1.1. Synthesis of Diclofenac-Glycine (DCF-Gly) ..................................................................... 10 
1.2. Nuclear magnetic resonance (NMR) analysis ................................................................... 11 
1.3. Electrospinning ................................................................................................................. 12 
1.4. Reverse phase high performance liquid chromatography (RP-HPLC) ............................ 13 
1.5. Cross-linking procedure .................................................................................................... 14 
1.6. Hyaluronic acid (HA) coating ........................................................................................... 14 
1.7. Swelling test analysis ......................................................................................................... 15 
1.8. Liquid displacement method .............................................................................................. 15 
1.9. Scanning electron microscopy (SEM). .............................................................................. 16 
1.10. Drug release experiments ................................................................................................ 16 
1.11. Contact angle measurements ........................................................................................... 17 
1.12. Uniaxial tensile testing .................................................................................................... 18 
1.13. Cell culture and seeding .................................................................................................. 18 
1.14. Multiphoton microscopy (MPM) ..................................................................................... 19 
1.15. In vitro cytotoxicity assay ................................................................................................ 20 
1.16. Fluorescence lifetime imaging microscopy (FLIM) ........................................................ 21 
1.17. ImageStream® analysis................................................................................................... 22 
1.18. Raman microspectroscopy. ............................................................................................. 23 
1.19. Data analysis ................................................................................................................... 23 
 
CHAPTER 2. IMAGING OF DICLOFENAC INDUCED CELL DEATH IN HUMAN 
DERMAL FIBROBLASTS USING MULTIPHOTON MICROSCOPY COUPLED 
WITH FLUORESCENCE LIFETIME IMAGING MICROSCOPY ............................... 24 
2.1. Introduction ..................................................................................................................... 24 
2.2. Results ............................................................................................................................... 26 
2.2.1. Production and characterization of the scaffolds .......................................................... 26 
2.2.1.1. Electrospinning ........................................................................................................... 26 
2.2.1.2. SEM and fiber diameter analysis ................................................................................ 26 
2.2.1.3. Drug release experiments ............................................................................................ 27 
2.2.1.3.1. UV-monitoring and fitting using Peppas equation ................................................... 28 
2.2.1.3.2. RP-HPLC .................................................................................................................. 28 
2.2.1.3.3. Electron X-ray dispersive spectroscopy (EDX) ........................................................ 30 
2.2.1.3.4. Nuclear magnetic resonance (NMR) analysis .......................................................... 32 
2.2.1.4. Tensile tests ................................................................................................................. 33 
2.2.1.5. Contact angle measurement ........................................................................................ 34 
2.2.1.6. In vitro cytotoxicity ...................................................................................................... 35 
2.2.2. MPM and FLIM analysis ............................................................................................... 35 
2.2.3. ImageStream® analysis.................................................................................................. 38 
2.2.4. MPM and FLIM real time analysis ................................................................................ 39 
2.3. Discussion ......................................................................................................................... 41 
2.4. Conclusions ...................................................................................................................... 46 
 
CHAPTER 3. PRODUCTION AND CHARACTERIZATION OF AN ELECTROSPUN 
PLA SCAFFOLD LOADED WITH A SYNTHETIC DICLOFENAC PRODRUG FOR 
THE LOCAL TREATMENT OF ACTINIC KERATOSIS. ............................................. 47 
3.1. Introduction ..................................................................................................................... 47 
3.2. Results ............................................................................................................................... 50 
3.2.1. Synthesis of a Diclofenac prodrug via SPPS .................................................................. 50 
3.2.2. Production of the scaffolds by electrospinning .............................................................. 50 
3.2.3. SEM and fiber diameter analysis ................................................................................... 50 
3.2.4. Contact angle measurements .......................................................................................... 52 
3.2.5. Tensile tests .................................................................................................................... 52 
3.2.6. MPM analysis ................................................................................................................. 53 
3.2.7. Drug release experiments ............................................................................................... 54 
3.2.8. In vitro cytotoxicity ......................................................................................................... 55 
3.2.9. FLIM analysis ................................................................................................................. 55 
3.3. Discussion ......................................................................................................................... 57 
3.4. Conclusions ...................................................................................................................... 62 
CHAPTER 4. HYBRID GELATIN/POLY-L-LACTIDE ELECTROSPUN 
SCAFFOLDS WITH CONTROLLED HYDROPHOBICITY AND WETTABILITY .. 63 
4.1. Introduction ..................................................................................................................... 63 
4.2. Results ............................................................................................................................... 69 
4.2.1. HYBRID GELATIN/POLY-L-LACTIDE SCAFFOLDS WITH CONTROLLED 
POROSITY AND WETTABILITY ............................................................................................. 69 
4.2.1.1. Production of the scaffolds by electrospinning and cross-linking .............................. 69 
4.2.1.2. SEM and fiber diameter analysis ................................................................................ 70 
4.2.1.3. Porosity, swelling properties and contact angle measurements ................................. 74 
4.2.1.4. Tensile tests ................................................................................................................. 76 
4.2.1.5. Raman spectra and principal component analysis (PCA) .......................................... 78 
4.2.1.6. Scaffolds biocompatibility ........................................................................................... 81 
4.2.2. HYBRID GELATIN/POLY-L-LACTIDE IN 1:1 RATIO SCAFFOLDS WITH 
CONTROLLED HYDROPHOBICITY ...................................................................................... 81 
4.2.2.1. Functionalization of the scaffolds with hyaluronic acid ............................................. 81 
4.2.2.2. SEM and fiber diameter analysis. ............................................................................... 82 
4.2.2.3. Porosity, swelling properties and contact angle measurements ................................. 84 
4.2.2.4. Tensile tests ................................................................................................................. 85 
4.2.2.5. Raman spectra and principal component analysis (PCA) .......................................... 87 
4.2.2.6. Scaffolds biocompatibility. .......................................................................................... 90 
4.2.3. MPM AND FLIM ANALYSIS OF HUMAN DERMAL FIBROBLASTS ON HYBRID 
GELATIN/POLY-L-LACTIDE SCAFFOLDS ....................................................................... 91 
4.2.3.1 MPM imaging ............................................................................................................... 91 
4.2.3.2 FLIM analysis ............................................................................................................... 92 
4.3. Discussion ......................................................................................................................... 95 
4.4. Conclusions ...................................................................................................................... 99 
 
SUMMARY AND CONCLUDING REMARKS ............................................................... 100 
SUPPLEMENTARY MATERIALS ................................................................................... 101 
REFERENCES ..................................................................................................................... 110 





















Siqua meis fuerint, ut erunt, vitiosa libellis, 
     excusata suo tempore, lector, habe. 
exul eram, requiesque mihi, non fama petita est, 
     mens intenta suis ne foret usque malis. 
 
Ovidio, Tristia, Liber IV, I, 1-4. 
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LIST OF ABBREVIATIONS 
 
[3-(4,5-dimethylthiazol-2-yl -5-(3-carboxymethoxyphenyl -2-(4-sulfophenyl -2H-tetrazolium] 
= MTS 
1,1,1,3,3,3-Hexafluoro-2-propanol = HFIP 
1-Hydroxybenzotriazole hydrate = HOBT 
2,2,2-Trifluoroethanol = TFE 
2-Chloro Trityl Chloride = 2-CTRL-Cl 
4, 4-dimethyl-4-silapentane-1-sulfonic acid = DSS 
7-aminoactinomycin D = 7-AAD 
Acetic acid = AcOH 
Acetonitrile = CH3CN 
Actinic keratosis = AK 
After release = a.r. 
Arbitrary unit = a.u. 
Aspartic acid = L-Asp 
Basal cell carcinoma = BCC 
Benzotriazol-1-yloxy-tripyrrolidino-phosphoniumhexafluorophosphate = PyBOP 
Cross-linked = X-linked 
CTRL = control 
Deuterated dimethyl sulfoxide = DMSO-d6 
Deuterium oxide = D2O  
Dichloromethane = DCM  
Diclofenac sodium salt = DCF  
Diclofenac-Glycine = DCF-Gly  
Dimethyl sulfoxide = DMSO  
Dimethylformamide = DMF  
Double distilled water = ddH2O  
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Dulbecco’s modified eagle medium = DMEM  
Electron X-ray dispersive spectroscopy = EDX  
Ethanol = EtOH  
Extracellular matrix = ECM  
Fetal calf serum = FCS  
Fluorescence lifetime imaging microscopy = FLIM  
Food and Drug Administration = FDA  
Fourier-transformed infrared spectroscopy = FTIR  
Gelatin = GE  
Glass-transition temperature = Tg  
Glutamic acid = L-Glu  
Glycosaminoglycan = GAG  
Gray value intensity = GVI  
Human dermal fibroblasts = HDFs  
Hyaluronic acid = HA  
Isoelectric point = IEP  
Matrix-assisted laser desorption ionization mass spectrometry = MALDI-MS  
Melting temperature = Tm  
Methanol = MeOH  
Multiphoton microscopy = MPM  
N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride = EDC·HCl  
N,N-Diisopropylethylamine = DIPEA  
Negative control = NC  
N-Hydroxysuccinimide = NHS  
Non-steroidal anti-inflammatory drugs = NSAIDs  
Nuclear magnetic resonance = NMR  
Phosphate buffer saline (1X) = PBS  
(DMSO containing) Poly-L-lactide scaffold = PLA (w DMSO)   
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(DMSO containing) Diclofenac sodium salt loaded poly-L-lactide scaffold = PLA + DCF (w 
DMSO)   
Diclofenac sodium salt loaded poly-L-lactide scaffold = PLA + DCF  
Diclofenac-Glycine loaded poly-L-lactide scaffold = PLA + DCF-Gly  
Poly-DL-lactic acid = PDLLA  
Poly(lactic-co-glycolic) acid = PLGA  
Poly-L-lactide = PLA; PLLA  
Positive control = PC  
Principal component analysis = PCA  
Reduced (phosphorylated) nicotinamide adenine dinucleotide = NAD(P)H  
Reverse phase high performance liquid chromatography = RP-HPLC  
Room temperature = r.t. 
Scanning electron microscopy = SEM  
Second harmonic generation = SHG 
Sodium dodecyl sulfate = SDS  
Solid phase peptide synthesis = SPPS  
Squamous cell carcinoma = SCC  
Stratum corneum = SC  
TFA = 2,2,2-Trifluoroacetic acid  
Time correlated single photon counting = TCSPC  
Two-photon-excitated fluorescence = TPEF  
Volume = v 
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One of the greatest challenges in the biomaterials field is to obtain versatile in vitro systems 
that can be easily controlled and adapted in order to reproduce properties that still belong only 
to in vivo models [1]. To reach this purpose the information and the technologies available 
nowadays must be combined together taking into account all the possible variables [2]. In the 
last 30 years, electrospinning has gained growing interest as a polymer processing technique 
for applications in tissue engineering and drug delivery [3]. Electrospinning is regarded as a 
simple approach for creating nanofibrous networks that can mimic the structure of the 
extracellular matrix (ECM). Interactions between cells and ECM are crucial to cellular 
differentiation and in regulating cell function [4–8]. Actually, the cells typically lose some of 
their normal in vivo behavior when they are removed from their microenvironment and 
cultured in vitro. A principal objective of tissue engineering, therefore, is to recreate in an in 
vitro culture system some of the essential factors of the cellular microenvironment, which 
control and regulate cell function in vivo. In this way, the high surface to volume ratio of 
nanofibrous electrospun scaffolds combined with their microporous structure can favor cell 
adhesion, proliferation, migration, and differentiation, all of which are highly desired 
properties for tissue engineering applications [9]. Electrospinning is a process that utilizes a 
high voltage source to inject charge of a certain polarity into a polymer solution or melt, 
which is then accelerated toward a collector of opposite polarity [3]. A typical electrospinning 
setup is shown in Fig.1. 
G.Piccirillo-Development of new in vitro models based on the use of electrospun scaffolds and their imaging by multiphoton 





Fig. 1. Schematic diagram of an electrospinning setup. 
The high surface to volume ratio of electrospun scaffolds can be also used for the efficient 
release of drugs after their incorporation in the scaffolds. After tissue engineering, drug 
delivery represents nowadays the second most exploited application field of electrospun 
scaffolds [3, 10-14]. Besides being a system that ensures a controlled and targeted drug-
delivery, nanofibrous electrospun scaffolds have also the benefit of being matrices that can 
favor the healing process [15]. In the last 20 years a variety of electrospun fibrous scaffolds 
for biomedical applications have been developed [9-23]. Biodegradable and natural materials 
can be electrospun, and a wide range of molecules as drugs and proteins can be incorporated 
in the scaffolds too [9-23]. To date, electrospinning has been applied for the fabrication of 
nanofibrous scaffolds from numerous biodegradable synthetic polymers, such as polylactic 
acid [16], polyglycolic acid [17], polyurethane [18] and the copolymer poly(lactic-co-
glycolic) acid [19]. Furthermore, incorporation of collagen and other biological components 
such as alginate [20], hyaluronic acid [21] and starch [22] into synthetic polymers was used to 
improve the scaffold biocompatibility or to introduce essential components of the ECM. In 
addition, the direct electrospinning of various biological substances, such as collagen, silk, 
fibrinogen, gelatin and chitosan, alone or together with synthetic polymers, has been 
investigated [23]. Since the scientific community has paid attention to electrospinning this 
technique has been regarded with constantly rising interest, and nowadays we have a great 
number of information about materials that can be electrospun and about their possible 
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applications [9-23]. Only some of them have been presented in this introduction and many 
new ones are daily investigated and published. However, the production of structures that can 
mimic biological tissues and samples is not the one and only goal when aiming to establish in 
vitro models that should be as close as possible to what happens in vivo. The development of 
methodologies that allow the dynamic imaging and analysis of living organisms in a neither 
invasive nor destructive way represents another great challenge [24]. Multiphoton microscopy 
(MPM) has grown extremely in this field since its first use for bioimaging [25]. MPM is a 
technique based on nonlinear optical processes such as two-photon-excited fluorescence 
(TPEF) or second harmonic generation (SHG). The simultaneous absorption of two photons is 
very unlikely to occur and short-pulsed femtosecond lasers operating in the near infrared 
(near-IR) are necessary [26, 27]. Nevertheless, the usage of this kind of lasers offers many 
advantages when aiming to image biological samples. For example, relative low average 
powers (in the milliwatts range) are needed for the analysis since the excitation is limited to 
the focal point. At the same time, no absorption and fluorescence occur above and below the 
plane of focus and so photobleaching and phototoxicity are generally avoided [27]. Not least, 
the use of excitation wavelength in the near-IR (700 nm or even greater) makes this technique 
less biologically harmful, and allows a deeper penetration in tissues or scattering samples 
when compared for example to confocal microscopy [27]. Moreover, many endogenous 
biomolecules (elastin, reduced nicotinamide adenine dinucleotide, flavin adenine 
dinucleotide) exhibit autofluorescence or are able to generate second harmonic signals 
(collagen) after excitation at specific wavelengths, and so they do not need to be stained [26-
29]. All these aspects make MPM a technique that allows high-resolution imaging of 
untreated samples without damaging them. To date, MPM has already been employed for the 
in vivo evaluation of basal cell carcinoma [29]. Besides the imaging, other information can be 
obtained from each single pixel of a MPM acquisition if the system is specifically modified. 
Fluorescence lifetime imaging microscopy (FLIM) represents one of the techniques that can 
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be coupled with MPM. FLIM allows, for example, the discrimination between fluorophores 
exhibiting different decay times [26, 27], or helps to gain information about cellular 
metabolism and biological microenviroment when having specific endogenous fluorophores 
as target molecules [28, 29]. The demand for versatile, reliable in vitro models will increase in 
the years ahead. One of the biggest limits of many in vitro models already available is that 
they can be highly specific and sensitive for particular applications, but they cannot be 
extended to other fields [30]. Thus, the challenge of creating new systems, easily adaptable 
depending on the final desired application, and that can be analyzed unmodified with non-
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OUTLINE AND OBJECTIVES 
 
In this PhD innovative in vitro applications for electrospun scaffolds are presented. Besides, 
multiphoton microscopy (MPM) coupled with fluorescence lifetime imaging microscopy 
(FLIM) has been employed for the imaging and the analysis of the samples, representing a 
neither invasive nor destructive methodology. These techniques have been combined together 
with the final aim of developing new versatile in vitro models. The work has been structured 
in three different parts. In the first part of the thesis (chapter 2) we aimed to develop a new 
model to assess drugs cytotoxicity in vitro. For this purpose the cytotoxic unmodified 
Diclofenac sodium salt (DCF) has been encapsulated in a pure poly-L-lactide (PLA) scaffold 
in order to obtain a system for its controlled release over time. A system ensuring a sustained 
drug release helps to better mimic a real therapeutic condition. The drug loaded scaffold has 
been then incubated together with human dermal fibroblasts (HDFs), before analyzing the 
cells exposed to the cytotoxic drug with MPM coupled with FLIM. These microscopies allow 
the imaging of unmodified biological samples without damaging them. In this thesis they have 
been chosen in order to develop a model to image morphological changes in the treated cells 
with MPM and evaluate their metabolic activity with FLIM. At the end, the use of an 
electrospun scaffold as a system for a specific and prolonged drug release together with the 
non-invasive analysis of the drug-exposed cells with MPM coupled with FLIM would offer a 
novel approach to investigate drugs cytotoxicity. In the second part of the thesis (chapter 3) 
we instead aimed to synthesize a non cytotoxic prodrug of DCF. Solid phase synthesis has 
been chosen representing a clean, versatile synthetic method. Moreover, we also aimed to 
encapsulate the synthesized DCF prodrug in a PLA scaffold and investigate in vitro its effects 
on HDFs comparing the prodrug to the cytotoxic DCF. To reach this purpose, a marker-free 
analysis of the unmodified cells based on the use of MPM coupled with FLIM is proposed. In 
the last part of the thesis (chapter 4), we aimed to obtain extracellular matrix (ECM) 
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mimicking scaffolds with tunable properties such as porosity and hydrophilicity and to 
investigate cell-material interactions in vitro with a non-invasive approach. To reach this 
purpose hybrid gelatin/PLA scaffolds have been produced by electrospinning, further 
modified and characterized. By blending naturally derived polymers with synthetic ones it is 
possible to obtain final structures with unique properties. Electrospinning allows the 
production of nanofibrous, high porous tridimensional scaffolds. Thus, this technique helps to 
obtain ECM-like final structures. According to our idea, by electrospinning gelatin, a 
biopolymer, together with PLA, a synthetic one, it may be possible to achieve final hybrid 
structures with unique properties that can be even further modified. Besides, we aimed to 
image cellular growth of HDFs on the hybrid scaffolds, and analyze their metabolic activity 
with MPM and FLIM, respectively. By working with hybrid electrospun scaffolds and 
analyzing them with a non-invasive methodology it would be possible to final obtain 
innovative versatile tridimensional in vitro models. On resuming, in this PhD thesis different 
applications of electrospun scaffolds are presented, while MPM and FLIM are proposed as 
imaging tools to analyze unmodified samples in a non-invasive, non-destructive and marker-
free way. At the end, we aim to demonstrate how the versatility of the electrospinning process 
and the use of MPM coupled with FLIM offer together a broad spectrum of possibilities for 
the development of versatile in vitro models that can be analyzed unmodified in a non-
invasive way. Particurarly, in this PhD these techniques have been combined together to 
finally develop in vitro models to investigate drugs cytotoxicity and cell-material interactions. 
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CHAPTER 1. MATERIALS AND METHODS 
1.1. Synthesis of Diclofenac-Glycine (DCF-Gly)  
Diclofenac-Glycine (DCF-Gly). 2-{2-[(2,6-dichlorophenyl)-(N-glycine)-amino]phenyl} 
acetic acid (C16H14Cl2N2O3). All coupling reagents were purchased from Novabiochem 
(EMD Millipore by Merck KGaA, Darmstadt, Germany). 2-chlorotrityl chloride resin 
preloaded with glycine (H-Gly-2ClTrt Resin), the solvents and DCF sodium salt (DCF) were 
purchased by Sigma-Aldrich (Steinheim, Germany). Diclofenac free acid was obtained by the 
dissolution of DCF in water followed by acidification and extraction [31]. For the synthesis, 
H-Gly-2ClTrt resin (227 mg, 0.250 mmol, substitution 1.1 mmol/g, mesh 75-150) was 
suspended in a solvent mixture (Dimethylformamide (DMF):Dichloromethane (DCM) = 1:1) 
to a  final volume of 10 mL, using a glass frittered disk sealed in glass column equipped with a 
faucet. The suspension was stirred (250 rpm) for 2 hours using an orbital shaker. The solvent 
was then removed by filtration and 8 mL of a DCM:DMF = 1:1 solution containing 148 mg 
(0.5 mmol) of Diclofenac free acid, 520 mg (1mmol) of Benzotriazol-1-yloxy-tripyrrolidino- 
phosphoniumhexafluorophosphate (PyBOP) and 150 mg (1mmol) of 1-Hydroxybenzotriazole 
hydrate (HOBT) were added to the resin. After shaking the mixture manually for a few 
minutes, 175 µL (1 mmol) of N,N-Diisopropylethylamine (DIPEA) was added and the 
mixture was shaken (280 rpm) using an orbital shaker for 20 hours. Thereafter, the solvent 
was removed by filtration, the resin was washed (2x10 mL DMF, 3x10 mL methanol 
(MeOH), 2x10 mL DMF, 3x10 mL DCM), and the functionalized amino acid was cleaved by 
adding 10 mL of a mixture of acetic acid (AcOH):2,2,2-Trifluoroethanol (TFE):DCM = 1:1:8. 
The solution was shaken (250 rpm) employing an orbital shaker for 30 minutes. The cleavage 
mixture was then filtered, and the resin was washed with DCM (3 x 5mL). The filtrates were 
combined and evaporated under reduced pressure to 5% of the initial volume, and 10 mL of 
double distilled water (ddH2O) was then added to precipitate the desired product. The final 
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product was lyophilized twice to remove any solvent residual, and recovered as a white fluffy 
powder in a final yield of 98% (86.5 mg, 0.245 mmol). The final product was characterized by 
nuclear magnetic resonance (NMR) and matrix-assisted laser desorption ionization mass 
spectrometry (MALDI-MS, analysis by Dr. Emiliano Bedini, University Federico II of 
Naples).
 1
H-NMR (500MHz, DMSO-d6): δ= 3.61 (s, 2H); 3.75 (d, J=5.6 Hz, 2H); 6.25 (d, J= 
8.0 Hz, 1H); 6.81 (t, J= 7.5 Hz, 1H); 7.00 (t, J= 7.9 Hz,1H); 7.12 (t, J =8.1 Hz, 1H); 7.18(d, 
J= 7.6 Hz, 1H) 7.47 (d, J= 8.2 Hz, 2H); 8.14(s, 1H); 8.63 (t, J= 5.6 Hz, 1H) ppm; 
13
C-NMR 
(500MHz, DMSO-d6): δ= 39.12, 41.35, 116.44, 121.14, 125.52, 125.72, 127.68, 129.61, 











1.2. Nuclear magnetic resonance (NMR) analysis 









C- NMR spectra were acquired at room temperature on a Inova 500 
NMR spectrometer (Varian, Agilent technologies, Inc., Palo Alto, CA, USA), equipped with a 
5 mm triple resonance probe and z-axial gradients operating at 500 MHz for 
1
H nuclei and 
125 MHz for 
13




C spectra were respectively set to 
chemical shift (δ) 2.49 and δ 39.5 for deuterated dimethyl sulfoxide (DMSO-d6). The pure 
DCF spectra were instead acquired in deuterium oxide (D2O, Sigma-Aldrich), adding 2µl of 4, 
4-dimethyl-4-silapentane-1-sulfonic acid (DSS) 10mM/D2O. Reference peak for 
1
H was in 
this case set to δ of 0.00 for DSS. The residual water signal signal was removed by double 
pulsed field gradient spin echo (DPFGSE) pulse sequence [32], in order to increase sensitivity 
of the receiver and thus reveal the signals of the highly diluted DCF solution extracted from 
the scaffold. All the acquired spectra were processed with ACD®/ NMR Processor Academic 
Edition (Advanced Chemistry Development, Inc., Toronto, Canada).  
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Poly-L-lactide (PLA, viscosity ~1.0 dL/g, 0.1% weight/volume (w/v) in chloroform (25°C), 
Mn 59000, Mw 101 kDa, ester terminated) and gelatin (GE, gelatin from bovine skin, type B, 
cell culture tested, Mw 50-100 kDa, Bloom strength ~225 Bloom) were purchased by Sigma-
Aldrich. The electrospun scaffolds were obtained starting from polymer solutions either 
containing or not the drug of interest too. When we aimed to obtain drug-loaded scaffolds the 
drug of interest was firstly allowed to complete dissolve before polymer addition. DCF-Gly 
was added to a final w/v% of 1%, while DCF to a final w/v% of 2% in chapter2 (when aiming 
to assess DCF cytotoxicity) and of 1% in chapter 3 (when aiming to compare it with DCF-
Gly), respectively.  After polymer(-s) addition the solutions were let stay at 37°C under 
magnetic stirring between 2 and 24 hours until they appeared completely clear. 1,1,1,3,3,3-
Hexafluoro-2-propanol (HFIP, Sigma-Aldrich) was used as solvent for all the experiments. 
When using dimethyl sulfoxide (DMSO, ≥99.9%, for molecular biology, Bioreagent, Sigma-
Aldrich) a 19:1 mixture represented the final HFIP:DMSO volume:volume ratio. All 
electrospinning experiments were performed with a customized device (Fig. 2).  
 
Fig.2. Electrospinning customized device. 
The parameters used for the electrospinning experiments are reported in Table 1. For the drug-
loaded electrospun scaffolds the parameters were the same used for pure PLA. In all cases an 
18G stainless steel needle was employed.  
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PLA 15 1 18 18 4 
GE 10 3 19.5 19 1.2 
GE:PLA=4:1 12.5 3 19.5 19 1.6 
GE:PLA=5:2 14 3 19.5 19 1.6 
GE:PLA=1:1 15 3 19.5 19 2.1 
Table 1. Parameters used in the electrospinning experiments. 
 
1.4. Reverse phase high performance liquid chromatography (RP-HPLC) 
All RP-HPLC analyses were performed on a Shimadzu (Shimadzu Europa GmbH, Duisburg, 
Germany) automated HPLC system supplied with a Jupiter C5 column (Phenomenex, 250 x 
4.6 mm, 5µ, 300 Å) with a flow rate of 1 mL/min, and UV detection. A binary gradient was 
used and the solvents were ddH2O with 0.1% TFA (2,2,2-Trifluoroacetic acid, Romil Super 
purity Solvent (SpS™), Romil Ltd, Waterbeach, Cambridge, UK) and HPLC purity grade 
acetonitrile (CH3CN, Romil Ltd). Products were eluted with a gradient of acetonitrile from 5 
to 70% over 30 min (540% over the first 10 min followed by 4050% over the next 15 
min and 5070% over the last 5 min). Reference chromatograms were obtained by injecting 
20 µL of a 1 mg/mL solution of the compound of interest in phosphate buffer saline 1X (PBS, 
Gibco™ by Life Technologies GmbH, Darmstadt, Germany). The reported chromatograms 
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1.5. Cross-linking procedure 
All solvents and reagents were purchased by Sigma-Aldrich unless stated otherwise. Sodium 
hyaluronate (molecular weight blend: 240kDa, 480kDa and 800kDa) was obtained by Simply 
Essential™ (Palmerston, New Zealand). For the cross-linking a solution in EtOH 95%/ 
ddH2O of N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC·HCl, 
Novabiochem®, EMD Merck Millipore) and N-Hydroxysuccinimide (NHS, Sigma-Aldrich) 
in equimolar ratio, both at the concentration of 50mM, was used. The electrospun scaffolds 
were immersed with a rate of 9mg/mL in a final mixture composed of the cross-linking and a 
sodium hyaluronate/ ddH2O (or pure ddH2O) solutions in a 9:1 volume:volume ratio, as 
described by Yang et al. [33]. Sodium hyaluronate/ ddH2O solutions with four different final 
w/v% (0.015%, 0.02%, 0.025%, 0.03%) were tested. After immersion, the scaffolds were 
shaken at room temperature (r.t.) for 24 hours using an orbital shaker (60 rpm). After the 24 
hours, the scaffolds were gently dried on filter paper and washed with ddH2O (3x used 
volume of the cross-linking mixture for each side). Thereafter, they were allowed to stay 24 
hours at 37°C in ddH2O (same volume used for the cross-linking mixture) and finally washed 
again with ddH2O (1x used volume of the cross-linking mixture for each side). After the 
washing procedure, the excess of water was removed using filter paper. The scaffolds were 
finally immersed in 70% EtOH/ddH2O (half the volume of the cross-linking mixture) for 30 
minutes, then dried on filter paper and allowed to stay overnight at r.t. to complete evaporate 
any solvent residual. 
 
1.6. Hyaluronic acid (HA) coating 
Cross-linked GE:PLA in a 1:1 weight:weight (w:w) ratio scaffolds were fully immersed at a 
rate of 9mg/mL in a 0.025% w/v HA solution in EtOH 85%/ ddH2O and gently mixed at r.t 
for 24 hours using an orbital shaker (60 rpm). Thereafter, the scaffolds were let dry overnight 
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at r.t., and used for further characterization either before or after being washed. The washing 
procedure was the same used for the cross-linked scaffolds, and described in the section 1.5.  
 
1.7. Swelling test analysis 
For each sample 16 different pieces obtained from four different scaffolds (4 pieces for each 
scaffolds) were employed. Each scaffold piece was immersed in 10 mL of ddH2O and allowed 
to mix at r.t. for 1 hour using an orbital shaker (60 rpm). After that time each side of the 
scaffold piece was let drip for 10 seconds. The excess of water was gently removed using 
filter paper, in case water drops on the scaffold surface were clearly visible. The rate of water 
absorbed by each piece was calculated according to the next shown formula (Scheme 1): 
𝑆𝑤𝑒𝑙𝑙𝑖𝑛𝑔 (%) =
𝑤𝑒𝑡 𝑠𝑐𝑎𝑓𝑓𝑜𝑙𝑑 𝑤 (𝑚𝑔) − 𝑑𝑟𝑦 𝑠𝑐𝑎𝑓𝑓𝑜𝑙𝑑 𝑤 (𝑚𝑔)
𝑑𝑟𝑦 𝑠𝑐𝑎𝑓𝑓𝑜𝑙𝑑 𝑤 (𝑚𝑔)
𝑥100 
Scheme 1. Formula used for the swelling test. 
 
1.8. Liquid displacement method 
The porosity of the scaffolds was estimated using the liquid displacement method, as 
previously described [34-36]. Absolute ethanol was used as the displacement liquid. Scaffold 
samples were immersed in a cylinder containing a known volume of absolute ethanol (V1) for 
30 minutes. After that time, the scaffold was gently pressed to remove air bubbles and the 
final volume represented by ethanol and ethanol-impregnated scaffold was recorded as V2. 
Finally the ethanol-impregnated scaffold was removed and the residual ethanol volume in the 





Scheme 2. Formula used for the porosity measurement according to the liquid displacement 
method. 
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1.9. Scanning electron microscopy (SEM) 
The morphology of the electrospun scaffolds was determined using a scanning electron 
microscope (1530 VP, Zeiss, Jena, Germany). After platinum sputter coating, images were 
acquired at a distance of 8 mm from the detector, a voltage of 15 kV and different 
magnifications. The ImageJ® software supplied with the DiameterJ plug-in was used for fiber 
diameter and pores size/number analyses. Electron X-ray dispersive spectroscopy (EDX) 
analyses were instead performed on a scanning electron microscope (E-SEM XL30, FEI, 
Eindhoven, The Netherlands) equipped with energy dispersive X-ray spectrometer (EDAX 
GEMINI 4000, Zeiss). A voltage between 4 and 10kV was used to focus on the unsputtered 
scaffolds, and then set to 30kV for the EDX analysis. The working distance was in this case 
set to 10 mm from the detector. The schematic diagram of the analysis is represented in Fig.3. 
EDX spectra were acquired and plotted by Mr. Alessandro Laurita (University of Basilicata, 
Potenza, Italy).  
 
Fig.3. Schematic diagram of the SEM and EDX analysis. 
 
1.10. Drug release experiments 
For the drug release experiments, the scaffolds were incubated at 37°C in PBS (Gibco™ by 
Life Technologies GmbH). In particular, 9 mg of the drug-loaded scaffolds were fully 
immersed in 3 mL of PBS. At different time points, 800 µL of the supernatant was taken to 
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read the absorbance. Reading wavelength was set to 272 nm. After each measurement we 
returned the supernatant to the scaffold containing solution. The amount of the released drug 
was estimated according to previously calculated calibration curves. Micro UV-cuvettes 
(BrandTech™ 759210, Brand™ by Thermo Scientific, Darmstadt, Germany) and a TECAN® 
Infinite 200 Reader were used for all the UV measurements. The final drug release profiles 
were obtained from 4 release experiments by each different scaffold. In all cases, the 
absorbance value at 272 nm was constant after the first 24 hours. This time was therefore set 
as the end point measurement. The amount of released drug was plotted over time. The 
obtained points (M(t)) were also fitted using the equation developed by Peppas et al. (Scheme 
3 [37,38]). The drug amount released after 24 hours was set as M(∞) in Peppas equation.  
𝑀(𝑡)
𝑀(∞)
= 𝑘 × 𝑡𝑛 
Scheme 3. Peppas-Korsmeyer equation [37, 38]. k represents the release rate constant while n 
the release exponent. 
 
1.11. Contact angle measurements 
Hydrophilicity of the electrospun substrates was analyzed using contact angle measurements 
with an OCA 40 device (DataPhysics Instruments GmbH, Filderstadt, Germany). A water 
drop with the volume of 2 µl was placed onto the sample and the contact angle was measured 
10 seconds after the water deposition using a video setup and the SCA20 software 
(DataPhysics Instruments) as previously described [39]. Final results were calculated from 16 
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1.12. Uniaxial tensile testing 
Electrospun scaffolds were cut into 10 mm × 20 mm rectangular pieces and clamped into the 
uniaxial tensile testing device (Electroforce 5500, ElectroForce® Systems Group, Bose 
Corporation, Minnesota, USA). The exact sample dimensions were determined before each 
measurement and recorded with the software for further calculations of the Young’s modulus 
(E-modulus) and the tensile strength. The scaffolds were pulled to failure by applying a 
stretch of 0.025mm/s. The Young’s modulus was calculated from the initial linear slope of the 
stress versus strain curve for each measurement. Measured values are presented as 
average±standard deviation (each group n=4). 
 
1.13. Cell culture and seeding 
All research was carried out in compliance with the rules for investigation of human subjects, 
as defined in the Declaration of Helsinki. This study was carried out in accordance with the 
institutional guidelines and was approved by the local research Ethics Committee (F-2012-
078). After informed written consent was given, skin biopsies were obtained and human 
dermal fibroblasts (HDFs) were isolated by enzymatic digestion as previously described [40]. 
Cells were cultured in Dulbecco’s modified eagle medium (DMEM, with L-Glutamine, 
Gibco™, Life Technologies GmbH) supplemented with 10% fetal calf serum (FCS, PAA 
Laboratories, Pasching, Austria) and 1% penicillin / streptomycin (100 U/mL Penicilium and 
100 μg/mL Streptomycin, Life Technologies GmbH). Cells were cultured in an incubator at 
37 °C and in a 5% CO2 atmosphere. Cell culture medium was changed every 3 days and cells 
were passaged or seeded using trypsin-EDTA (15090046, PAA Laboratories) at 
approximately 70% confluence. When seeding the cells directly on electrospun scaffolds, 
HDFs were seeded in number of 7x10
5
 in 12-well plates using inserts (CellCrown™, 
Scaffdex, Tampere, Finland). In this case, cells were analyzed 24 hours after seeding. 
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1.14. Multiphoton microscopy (MPM) 
A titanium-sapphire femtosecond laser (MaiTai XF1, Spectra Physics, Santa Clara, USA) was 
used to generate 2-photon excitation. An excitation wavelength of 710 nm and a laser power 
of 3.2 mW were employed. The spectral emission filter ranged from 425 to 509 nm. For the 
imaging of the drug encapsulation, punches (Ø =12 mm) of the scaffolds were put on Ibidi® 
(Ibidi GmbH, Planegg/Martinsried, Germany) glass bottom dishes (35mm) and carefully 
pressed on the bottom with a cover glass before analysis. HDFs morphology was assessed on 
glass bottom dishes (Ibidi®, 35mm) with a density of 5 x 10
4 
cells per dish. After 24 h, the 
medium was removed and 2 mL of fresh DMEM (+ 10% FCS) was added. When the cells 
were incubated with the (drug-loaded) scaffolds, punches (Ø=28 mm) of previously sterilized 
(254 nm, 2 hours) scaffolds were given as well. When analyzing HDFs, the laser power was 
adjusted to 18 mW. The experimental setup is schematized in Fig. 4.  
 
Fig. 4. Experimental setup for the MPM experiments. 
When imaging cells directly on scaffolds, the electrospun scaffolds were instead removed 
from the inserts, flipped and carefully pressed on the bottom with a cover glass before 
analysis. For the mean gray value intensity (GVI) analysis of the drug-loaded scaffolds, 
ImageJ® was used as software to process and analyze the images. 
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1.15. In vitro cytotoxicity assay 
According to an ISO 10993 accredited protocol, HDFs were exposed to an extract of the 
samples. The test was carried out as previously described [41]. In particular, the electrospun 
scaffolds were sterilized by UV irradiation (254nm) for 2h. 6cm
2 
of each sample was then 
incubated in 1 mL FCS- and antibiotic-free DMEM medium. Each extract was prepared in 
triplicate. After 24 hours (72 hours in the case of the hybrid GE/PLA scaffolds, chapter 4), 
seeded HDFs were exposed for further 24 hours to the extracts supplied with 10% FCS. The 
extraction medium was removed and a tetrazolium salt ([3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium], MTS, Fig. 5) assay (CellTiter 
96Aqueous One Solution Cell Proliferation Assay, Promega, Mannheim, Germany) was 
performed as per the manufacturer’s protocol.  
 
Fig. 5. Mechanism of the reduction reaction of MTS to Formazan. 
Briefly, 20 µL of MTS solution was added to 100 µL of culture media. After incubation for 35 
minutes at 37°C, the absorbance of each well was measured at 492 nm using a TECAN® 
Infinite 200 Reader. The test was performed for a blind, a negative control (NC; DMEM + 
10% v FCS) and a sodium dodecyl sulfate (SDS, Life Technologies GmbH, 1% w/v in 
DMEM) treated positive control (PC). The procedure used to perform the MTS assay is 
schematized in Fig. 6. For analysis, the NC was set to 100%. 
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Fig.6. Schematic diagram of the protocol employed to perform the MTS assay. 
 
1.16. Fluorescence lifetime imaging microscopy (FLIM) 
FLIM was performed to assess reduced (phosphorylated) nicotinamide adenine dinucleotide 
(NAD(P)H) using time correlated single photon counting (TCSPC) at an excitation 
wavelength of 710 nm and a laser power of 18 mW. Analyzed samples were handled as 
described for MPM in section 1.14. FLIM data were recorded at an acquisition time of 180s 
for 512x512 pixels with 64 time channels. The instrument response function was recorded 
using urea crystals (Sigma-Aldrich) at an excitation wavelength of 920 nm and a laser power 
of 4.5 mW for 120s. The FLIM images were analyzed using the SPCImage software (Becker 
&Hickl GmbH, Berlin, Germany). A biexponential decay fitting model (Scheme 4) was 
employed at each pixel since NAD(P)H has two different lifetimes represented by τ1 and τ2 
[42]. A χ
2
<1.1 was accepted for a good fitting.  
𝐼(𝑡) = 𝛼1𝑒
−𝜏1 + 𝛼2𝑒
−𝜏2 + 𝐶  
Scheme 4. Biexponential decay fitting used for the FLIM analysis. τ1 represents the free 
NAD(P)H lifetime time, while τ2 the protein bound NAD(P)H one. 
A binning factor of 6 was used in the analysis. Final data arise from 4 different donors. For 
each donor 3 different dishes were seeded with cells (50000 cells/dish) and 5 images were 
acquired per dish at each different time point. Between the different time point measurements 
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the dishes with the seeded cells were returned to 37°C/5%CO2. By the real time and 
ImageStream® analyses (sections 3.2.2 and 3.2.3.), and when imaging HDFs on scaffolds 
(section 4.3.3.), only one donor was considered. Mean values arise in these cases from 12 
images for each experimental point obtained from 3 different dishes (4 images/dish).  
 
1.17. ImageStream® analysis 
Annexin V (Annexin V Apoptosis Detection Kit eFluor™ 450) and 7-aminoactinomycin D 
(7-AAD, 7-AAD Viability Staining Solution) were purchased from eBioscience™ (part of 
Thermo Fischer Scientific, Darmstadt, Germany). By the analysis, for each group cells were 
obtained from three different dishes that were previously analyzed with FLIM as described in 
the 1.16 section. After FLIM analysis, cells were treated with trypsin-EDTA (PAA 
Laboratories), recovered per centrifugation, counted and washed (PBS, Gibco
TM
). Thereafter, 
cells were harvested and stained with Annexin V eFluor™ 450 and 7-AAD as per the 
manufacturer’s protocol. In particular, the cells were re-suspended at a rate of 10
6
 cells/mL in 
Annexin V binding buffer (1X binding buffer diluted with ddH2O from the starting 10X 
buffer). Samples were then stained with Annexin V-FITC (ApopNexin™ FITC, APT750a, 
Merck Millipore) and 7-AAD in Annexin V binding buffer (5 μL of fluorochrome-conjugated 
to 100 μL of the cell suspension) and left for 10 min at r.t. protecting from light. After that 
time, they were immediately placed on ice before analysis on an ImageStreamX Mark II 
(Amnis® part of Merck Millipore, Darmstadt, Germany) supplied with the INSPIRE 
(Amnis®) instrument controller software. The resultant data, obtained from at least 10000 
cells/sample were then analyzed with the IDEAS (Amnis®) software. All samples were gated 
on single cells in focus (40X magnification) and then analyzed for Annexin V and 7-AAD. 
All ImageStream® analyses were carried out by Simone Pöschel (M.Sc., Women’s hospital, 
University of Tübingen, Germany). 
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1.18. Raman microspectroscopy 
The Raman system and acquisition parameters used in this study were previously described 
[43]. Briefly, a 784 nm diode laser with an output laser power of 85 mW was focused through 
a water-immersion objective (60X, NA 1.2, Olympus, Tokyo, Japan). The total acquisition 
time per spectrum was 100 s (10x10s acquisitions). All Raman spectra were analyzed in the 
range from 700 to 1800 cm
-1
. Spectra were background-subtracted, baseline-corrected and 
vector-normalized using OPUS (Bruker Optics, Ettlingen, Germany) and Unscrambler X 10.3 
(Camo, Oslo, Norway) as previously described [43]. Principal component analysis (PCA) was 
performed using Unscrambler X 10.3 (Camo) to reduce spectral variables and identify spectral 
differences among the compared samples. Seven PCs were calculated for each PCA. PC 
loadings were considered in detail to identify the molecular components that were relevant for 
the comparison of the spectra. 
 
1.19. Data analysis 
All the reported graphs were plotted using Microsoft™ Excel. All data are presented as 
mean±standard deviation (n=4, unless stated otherwise in the materials and methods). 
Statistical significance was determined by a Student’s two-tailed unpaired t-test. Either p≤0.01 
(**) or p≤0.05 (*) were defined as statistically significant. 
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CHAPTER 2. IMAGING OF DICLOFENAC INDUCED CELL DEATH IN HUMAN 
DERMAL FIBROBLASTS USING MULTIPHOTON MICROSCOPY COUPLED 
WITH FLUORESCENCE LIFETIME IMAGING MICROSCOPY  
2.1. Introduction 
Diclofenac (as a sodium salt, DCF) is one of the most sold and used non-steroidal anti-
inflammatory drugs (NSAIDs) prescribed to millions of people worldwide [44, 45]. DCF is 
successfully used to treat osteoarthritis, rheumatoid arthritis [46, 47] and muscle pain [48], 
among others [49]. Besides, Diclofenac exhibits also anticancer effects, like other anti-
inflammatory drugs [50-53] and is, for example, efficiently employed for the treatment of 
actinic keratosis (AK) in combination with hyaluronic acid (HA) [54]. DCF pharmaceutical 
properties are mainly releated to its activity as a potent non-selective cyclooxygenase inhibitor 
[45, 55]. However, scientists have been widely researching on other possible explanations for 
its complex mechanism of action [56]. Many progresses have been made thus far also to 
explain the toxic side-effects related to (prolonged) DCF therapies [57-64]. Diclofenac 
toxicity is proved in both animals [58] and humans [59]. Tomic et al. [60] and a few other 
studies [61-64] have shown the hepato- and nephro-toxicity of DCF. Detailed analysis of 
single patients has revealed clinical features that could be compatible with a direct toxic effect 
of DCF or any of its metabolites [65], rather than a drug-allergy mechanism [66-69]. Since the 
liver toxicity represents the most reported complication related to a prolonged or high-dosage 
use of DCF, in vitro studies have been mainly carried out using hepatocytes as target cells. To 
date, many different studies with cultured hepatocytes from various species have proved that 
high DCF concentrations (400 µM to 500 µM) are able to induce acute cell injury [70-77]. 
Recently, in vitro toxicity of DCF has been demonstrated also in other cell lines [78-82]. 
However, the mechanism behind DCF acute cellular toxicity has not been clearly determined, 
and the use of such high concentrations has been questioned, as it doesn’t mimic a clinical 
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therapeutic situation. While DCF hepato- [61-68, 83-85] and nephro-toxicity [58-60] has been 
widely investigated, not that much is known about its activity as an anti-cancer drug [49-54]. 
For example, the mode of action of DCF in combination with HA in the local treatment of 
cutaneous AK is largely elusive, but its chemotherapeutic activity could be associated with 
drug induced apoptosis [86, 87]. In this thesis we proved DCF induced cell death in human 
dermal fibroblasts (HDFs) using a new effective, non-destructive in vitro model. Herein, 
HDFs were incubated together with a DCF-loaded electrospun poly-L-lactide (PLA) scaffold, 
which ensured to obtain a controlled drug release over 24 hours. The DCF exposed cells were 
imaged using multiphoton microscopy (MPM) and their metabolic activity was investigated 
using fluorescence lifetime imaging microscopy (FLIM). For the FLIM and MPM analysis 
reduced (phosphorylated) nicotinamide adenine dinucleotide (NAD(P)H), an endogenous 
fluorophore, was chosen as target [88]. NAD(P)H is mainly present in the mitochondria and 
directly involved in the ATP synthesis [89] which are both damaged in the cells after DCF 
exposure [90, 91]. Induced apoptotic and necrotic events were observed and then confirmed 
with ImageStream® analysis [92]. Besides, we investigated how the use of dimethyl sulfoxide 
(DMSO) as a co-solvent system in the electrospinning affected the scaffold morphology and 
its properties. Herein, we demonstrated that DMSO, a high boiling solvent, was not 
completely evaporated under our experimental conditions, thus being retained in the 
electrospun fibers. However, after water immersion DMSO diffused from the scaffold which 
regained the morphology typical of electrospun structures. Moreover, when the drug-loaded 
scaffolds were characterized we found that while diffusing DMSO enhanced DCF initial burst 
release. This aspect could be of great interest when producing nanofibrous scaffolds for drug 
delivery by electrospinning, also considering that DMSO is efficiently employed as a skin 
penetration enhancer in many pharmaceutical formulations [93, 94]. The effects of the 
presence of DMSO on the scaffold morphology were investigated using scanning electron 
microscopy (SEM). Besides, the effective release of DCF and DMSO from the electrospun 
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scaffolds was proved with energy-dispersive X-ray spectroscopy (EDX), reverse-phase high 
performance liquid chromatography (RP-HPLC) and nuclear magnetic resonance (NMR). The 
obtained results suggest that the here described model could represent an interesting way to 




2.2.1. Production and characterization of the scaffolds 
2.2.1.1. Electrospinning 
PLA was dissolved in HFIP (+DMSO) either alone or in presence of DCF. Various 
electrospinning parameters were tested and those leading to stable Taylor’s cone and jet as 
well as to smooth and uniform fibers (Fig.7 A-C, G-I and Fig.8 A-C, G-I) were then used 
throughout the study. The conditions were first defined for pure PLA and then adapted for the 
other (drug-loaded) scaffolds.  
 
2.2.1.2. SEM and fiber diameter analysis 
The morphology and fiber sizes of the scaffolds, before and after PBS immersion (after 
release, a.r.) was investigated using SEM (Fig.7 A-C, G-I and Fig.8 A-C, G-I). It was possible 
to generate scaffolds with a random fiber orientation. In all conditions, we obtained uniform 
scaffolds (Fig.7 A-C and Fig.8 A-C) but when using DMSO the fibrous morphology of the 
electrosun scaffolds appeared altered (Fig.7 A, C and Fig.8 A, C). After drug release (Fig.7 G-
I and Fig.8 G-I), morphological changes were clearly visible in the samples electrospun using 
DMSO (Fig.7 G, I and Fig.8 G, I). In all cases, after the release experiment, the fibers were 
still uniform and randomly oriented (Fig.7 G-I and Fig.8 G-I). When using no DMSO the 
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fiber size was not affected after the drug release (PLA + DCF: 143±6 nm versus PLA + DCF 
a. r.: 146±9 nm; p=0.74). In all other cases there was a significant decrease in fiber size after 
24 hours PBS immersion (PLA (w DMSO): 317±6 nm versus PLA (w DMSO) a.r.: 179±7 
nm; p=0.004; PLA + DCF (w DMSO): 187±10 nm versus PLA + DCF (w DMSO) a.r.: 134±6 
nm; p=0.008). Besides, when encapsulating DCF the fiber size significantly decreased (PLA + 
DCF (w DMSO) versus PLA (w DMSO), p=0.005). This happens probably because of the use 
of DCF as sodium salt, which enhances the conductivity of the solution used for the 
electrospinning experiment. A similar behavior was found by Kim et al. when working with 
the antibiotic cefoxitin sodium [95]. All the significant differences observed in the fiber size 
are shown in Fig.7M (**: p≤0.01).  
 
2.2.1.3. Drug release experiments 
2.2.1.3.1. UV-monitoring and fitting using Peppas equation 
The ability of the scaffold to release the drug was firstly investigated by UV detection. The 
absorbance at 272 nm of the PBS solution, in which the drug-loaded scaffold was immersed, 
was constantly monitored for the first 6 hours and then was measured again after 24, 48 and 
72 hours. In order to be sure that the absorbance was not affected by the release of solvent 
residuals, absorbance values were corrected against a blank represented by a PBS solution 
containing a pure PLA or a PLA (w DMSO) scaffold for the PLA + DCF scaffold and the 
PLA + DCF (w DMSO) scaffold, respectively. In all cases by the release experiments, the 
absorbance value at 272 nm was constant after the first 24 hours. This time was therefore set 
as the end point measurement. The amount of released drug was plotted over time (Fig.7N). 
The obtained points were also fitted using the equation developed by Peppas et al. (Fig.7O). 
The drug amount released after 24 hours was set as M(∞) in Peppas equation. Peppas equation 
offers a simple model to study the release mechanism of incorporated molecules from 
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polymers [37, 38, 96, 97]. No significant differences (p=0.82) in the release exponent (n) 
could be found between the sample containing DCF alone and the one containing DCF and 
DMSO, since the obtained values were 0.10±0.02 and 0.10±0.03 (p=0.87), respectively. In 
both cases the exponent values suggest that the release undergoes a controlled diffusion [97]. 
According to our results, the use of DMSO affects the initial burst release of the drug since 
the obtained values for the release rate constant (k) were 0.67±0.4 h
-0.1
 and 0.42±0.3 h
-0.1 
(p=0.003), when having DMSO or not, respectively. 
 
2.2.1.3.2. RP-HPLC 
The effectiveness of the DCF release from the scaffolds was verified using RP-HPLC. A 
binary gradient of CH3CN/ddH2O from 5 to 70% over 30 minutes (540% over the first 10 
min followed by 4050% over the next 15 min and 5070% over the last 5 min) was used 
allowing a good separation for pure DCF in PBS (retention time: 19.7 min by 46.7% CH3CN/ 
ddH2O, Fig.S1A). The same conditions were then used also for the elution of the supernatant 
of the scaffold extracts. In all cases, DCF with a high purity could be eluted indicating that the 
encapsulated drug doesn’t undergo any side-reaction during the electrospinning process. 
Chromatograms are reported in the supplementary materials section (Fig.S1B and Fig.S1C for 
DCF, released from pure PLA and PLA with DMSO, respectively).  
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Fig.7. A-C and G-I. SEM images of the electrospun scaffolds at 2kX magnification before (A-
C) and after (G-I) 24h PBS immersion (after release, a.r.). Scale bars equal 50 µm. A. Pure 
PLA (w DMSO); B. PLA + DCF; C. PLA + DCF (w DMSO). G. Pure PLA (w DMSO) a.r.; 
H. PLA + DCF a.r.; I. PLA + DCF (w DMSO) a.r. D-F and J-L. Histograms for the fiber 
distribution of the electrospun scaffolds before (D-F) and after (J-L) 24h PBS immersion 
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(a.r.). D. Pure PLA (w DMSO); E. PLA + DCF; F. PLA + DCF (w DMSO). J. Pure PLA (w 
DMSO) a.r.; K. PLA + DCF a.r.; L. PLA + DCF (w DMSO) a.r.  M. Fiber mean diameter 
comparison after ImageJ® segmentation and DiameterJ® analysis. N-O. Drug-release profile 
(N) and fitting according to Peppas-Korsmeyer model (O) for the PLA + DCF scaffold (red 
squares) and the PLA + DCF (w DMSO) scaffold (blue rhombi).    
 
2.2.1.3.3. Electron X-ray dispersive spectroscopy (EDX) 
The effective DCF encapsulation and its release from the PLA scaffolds were verified with 
EDX analysis as well (Fig.8 D-F and Fig.8 J-L). Carbon (C) and Oxygen (O) signals arose 
mainly from PLA and did not allow us to assign them to the other molecules. Sulfur (S) signal 
was attributed to the presence of DMSO. Chlorine (Cl) and Sodium (Na) revealed instead the 
presence of DCF (Fig.8 D-F). After 24 hours PBS immersion (after release, a.r.), neither S nor 
Cl and Na signals could be detected (Fig.8 J-L), suggesting the diffusion of DMSO and DCF, 
respectively. Entire EDX spectra are reported in the supplementary materials (Fig.S2A-S6F) 
together with two example SEM images of the unsputtered scaffolds acquired to focus on the 
samples (Fig.S3). 
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Fig.8. A-C and G-I. SEM images of the electrospun scaffolds at 10kX magnification before 
(A-C) and after (G-I) 24h PBS immersion (after release, a.r.). Scale bars equal 10 µm. A. Pure 
PLA (w DMSO); B. PLA + DCF; C. PLA + DCF (w DMSO). G. Pure PLA (w DMSO) a.r.; 
H. PLA + DCF a.r.; I. PLA + DCF (w DMSO) a.r. D-F and J-L. EDX spectra of the 
electrospun scaffolds before (D-F) and after (J-L) 24h PBS immersion (after release, a.r.) 
between 0 and 3.3 keV. D. Pure PLA (w DMSO); E. PLA + DCF; F. PLA + DCF (w DMSO). 
J. Pure PLA (w DMSO) a.r.; K. PLA + DCF a.r.; L. PLA + DCF (w DMSO) a.r. 
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2.2.1.3.4. Nuclear magnetic resonance (NMR) analysis 
NMR analysis of the supernatant was done, after water removal by freeze-drying. PBS salts 
cannot be revealed by 
1
H-NMR, and so did not affect the analysis. DCF 1mg/mL in D2O was 
used as reference for signal comparison (Fig.9A). According to the NMR results, DCF 
diffused from both pure PLA (Fig.9B) and PLA with DMSO (Fig.9C). DMSO could be 
detected as well (singlet, δ = 2.71 ppm [98]) after its diffusion from PLA with DMSO 
(Fig.9C). The water signal (singlet, δ = 4.79 ppm [99]) could not be completely removed 
when using samples from the release experiments because the samples were too diluted 




H-NMR spectra in D2O of pure DCF. B, C. 
1
H-NMR spectra of the extracts in PBS 
of DCF-loaded PLA (B) and DCF-loaded PLA (w DMSO) (C) scaffolds after water removal 
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2.2.1.4. Tensile tests 
PLA is an elastic and electrospinnable polymer. Pure electrospun PLA was previously 
characterized [88]. Representative stress-strain experimental curves are shown in Fig.10A-C. 
Generally, the mechanical properties of PLA were affected by the addition of DCF and 
DMSO (Fig.10A-E). The DCF encapsulation lowered the scaffold elasticity (Fig.10D, E-
modulus, PLA + DCF: 133.8±13.6 MPa versus PLA: 24.4±9.7 MPa [88], p=0.0002; PLA + 
DCF (w DMSO): 74.8±9.7 MPa versus PLA (w DMSO): 14.0±1.2 MPa, p=0.004). Opposite, 
DMSO retain improved scaffolds elasticity, lowering the E-modulus (Fig.10D, PLA (w 
DMSO) versus PLA, p=0.0012; PLA + DCF (w DMSO) versus PLA + DCF, p=0.006). 
Generally, the E-modulus decreased with the increasing fiber diameter as previously 
described [100, 101]. However, the DCF encapsulation strongly increased the E-modulus, 
making the scaffold structure less elastic (Fig.10D). Not so big differences could be found in 
regards to tensile strength (Fig.10E). Nevertheless, pure PLA showed the highest tensile 
strength (1.84±0.19 MPa [88]). Actually, the addition of either DCF or DMSO as well as both 
of them led to significantly lower tensile strength values (Fig.10E, PLA (w DMSO): 
0.83±0.18 MPa; PLA + DCF: 1.02±0.19MPa; PLA + DCF (w DMSO): 1.37±0.17 MPa) when 
compared with pure PLA (p≤0.01 in all cases). Moreover, the scaffold containing both DCF 
and DMSO showed a tensile strength significantly higher when compared to the other PLA 
scaffolds containing only one of the two encapsulated molecules (Fig.10E, PLA + DCF (w 
DMSO) versus PLA (w DMSO), p=0.0034; PLA + DCF (w DMSO) versus PLA + DCF, 
p=0.0073). According to these results we suggest that the DCF encapsulation alters the PLA 
mechanical properties, but no direct correlations between the fiber morphology and the 
scaffold properties can be determined. On the other hand, DMSO encapsulation lowers E-
modulus and tensile strength values. That finding can be correlated with the increase in the 
fiber size (Fig.7M) according to literature data [100, 101].  
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2.2.1.5. Contact angle measurements  
Wettability of the scaffolds was determined using contact angle measurements. The analysis 
showed that the hydrophobicity of the scaffolds was not significantly affected by the presence 
of DCF and/or DMSO (Fig.10F). No significant changes were observed in the contact angle 
values for all the scaffolds characterized in this work (Fig.10F, PLA w DMSO: 132±2°; PLA 
+ DCF: 129±3°; PLA + DCF w DMSO: 131±3°) when compared to pure PLA (131±7°, [88]). 
The measurements suggest that all the scaffolds remained hydrophobic (Fig.10E). 
 
Fig.10. Analysis of the mechanical/physical properties of the electrospun scaffolds. A-C. 
Representative stress-strain curves of: a DMSO-containing PLA (PLA (w DMSO)) scaffold 
(A), a DCF-loaded PLA (PLA + DCF) scaffold (B) and a DMSO-containing DCF-loaded 
PLA (PLA + DCF (w DMSO)) scaffold (C). D.Comparison of the elastic modulus (E-
modulus) among the PLA (w DMSO), PLA + DCF and PLA + DCF (w DMSO) scaffolds. E. 
Comparison of the ultimate tensile strength among the PLA (w DMSO), PLA + DCF and 
PLA + DCF (w DMSO) scaffolds. F. Contact angle values, after water drop deposition, of the 
PLA (w DMSO), PLA + DCF and PLA + DCF (w DMSO) scaffolds. 
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2.2.1.6. In vitro cytotoxicity 
The biocompatibility of the modified scaffolds was assessed with a MTS assay [102] using a 
standardized protocol and HDFs as cells, as previously described [88]. Accordingly, we 
determined that the use of DMSO did not affect PLA scaffold biocompatibility (cell 
proliferation: PLA (w DMSO) = 102±7%). On the other hand, the DCF containing scaffolds 
showed a severe cytotoxicity towards HDFs (cell proliferation: PLA + DCF = 12±1%; PLA + 
DCF (w DMSO) = 13±2%, p≤0.01 in both cases when compared to the NC). Thus, we 
assessed the scaffolds cytotoxic effects as a result of the DCF release, while the DMSO 
concentration in the extracts was probably too low to determine cytotoxic effects [103-105]. 
The results of the MTS assay are reported in the supplementary materials (Fig.S4).  
 
2.2.2. MPM and FLIM analysis 
MPM and FLIM analyses were performed to analyze endogenous NAD(P)H in HDFs and to 
detect metabolic changes and cytotoxic effects in the target cells due to the incubation 
together with the drug-loaded scaffolds. In order to demonstrate that the observed cytotoxicity 
would be due to DCF and not to the presence of the scaffold itself limiting, for example, the 
oxygen exchange, the measurements were carried out either in presence or in absence of a 
pure PLA scaffold by using as control HDFs on glass. Besides, the treated cells were analyzed 
also after the removal of the scaffold. In all cases, no significant differences after 24 hours 
incubation time in the α1(%) and τs values could be found between the compared samples 
(Fig.S5). Once assessed that the presence of the scaffold did not affect the FLIM 
measurements, we decided to investigate the supposed DCF cytotoxicity towards HDFs after 
its release from PLA scaffolds. The DCF-loaded scaffolds used by the FLIM analysis were all 
electrospun without DMSO, in order to limit the variables and to ascribe the potential 
cytotoxicity only to DCF. The in vitro system described in this thesis ensured us to have a 
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controlled drug release over 24 hours. Two different time points, 6 and 24 hours, were chosen. 
The first one represented the reaching of a maximum in the drug release profile (Fig.7N), 
while the second one represents the incubation time used for the MTS assay. The control 
(CTRL) was also measured after 6 and 24 hours (times refer to the incubation time after 
having changed the culture medium, 24 hours after cell seeding). However, since no 
significant differences in the α1 and τs values could be found in the CTRL for the two 
different time points, only the values obtained after 6 hours incubation were analyzed. Besides 
the FLIM analysis, MPM images were acquired to monitor cell morphology. Cell morphology 
appeared altered in the treated cells already after 6 hours (Fig.11B) when compared to the 
control (Fig.11A). However, cell showing the normal elongated fibroblasts shape could still 
be imaged after the first 6 hours DCF exposure (Fig.11B). After 24 hours cell morphology 
appeared completely different from the one of the control. In particular, cells that showed a 
nuclear and cytoplasmic condensation were assessed as apoptotic (Fig.11C), while cells 
showing both swelling and vacuolation of the cytoplasm were considered to undergo necrosis 
(Fig.11D), as previously described by Seidenari et al. [28]. According to the FLIM analysis 
already after 6 hours a significant increase in the τ1 values (Fig.11E, τ1 CTRL: 0.63±0.02 ns 
versus τ1 DCF/6h: 0.72±0.02 ns, p=0.003) as well as a significant decrease in the α1% values 
could be detected for the DCF-exposed cells, when compared with the control (Fig.11F, α1% 
CTRL: 73.3±0.9% versus α1% DCF/6h: 63.9±1.1%, p=0.002). After 24 hours incubation a 
significant increase in the τ1 values could still be found for the treated sample when compared 
with the control (Fig.11E, τ1 CTRL: 0.63±0.02 ns versus τ1 DCF/24h: 0.74±0.02 ns, 
p=0.0025). On the other side, the difference in the τ1 values after 24 hours was not significant 
when compared to the ones obtained after 6 hours (Fig.11E, τ1 DCF/6h: 0.72±0.02 ns versus 
τ1 DCF/24h: 0.74±0.02 ns, p=0.47). The α1% values of the samples after 24 hours incubation 
instead significant decreased when compared to both control (Fig.11F, α1% CTRL: 
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73.3±0.9% versus α1% DCF/24h: 62.1±1.2%, p=0.0016) and 6 hours exposed cells (Fig.11F, 
α1% DCF/6h: 63.9±1.1% versus α1% DCF/24h: 62.1±1.2%, p=0.0084).  
 
Fig.11. MPM imaging (A-D) and FLIM analysis (E, F) of HDFs exposed to a DCF-loaded 
PLA scaffold. A-D Untreated HDFs (A); DCF-treated HDFs after 6h incubation time (B); 
DCF-treated HDFs assessed as apoptotic (C) and necrotic (D) after 24h incubation time. Scale 
bar equals 20 µm. E. Comparison of the τ1 values among control (CTRL) and DCF-treated 
samples after 6 and 24h. F. Comparison of the α1 (%) values among CTRL and DCF-treated 
samples after 6 and 24h. G. Comparison of the nucleus diameter values among normal 
untreated fibroblasts (CTRL) and DCF-treated cells assessed either as apoptotic or necrotic. 
According to these morphological changes, we were also able to determine changes in the 
nucleus diameter [28] of the fibroblasts after the 24 hours DCF exposure (Fig.11G). In 
particular, cells assessed as apoptotic showed a significant decrease in the nucleus diameter 
when compared to the untreated samples (Fig.11G, DCF/apoptotic: 7.8±1.7 µm versus CTRL: 
13.1±2.2 µm, p=0.007). On the other hand, necrotic cells had an increase in the nucleus 
diameter (Fig.11G, DCF/necrotic: 18.7±1.4 µm versus CTRL, p=0.008) due to a significant 
cytoplasmatic swelling. 
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2.2.3. ImageStream® analysis 
DCF induced cell death was proved with ImageStream® since it is considered a reliable 
method [92]. In particular, Annexin V was used as a marker for apoptosis (blue staining) and 
7-AAD for necrosis (red staining, Fig.12A). It was also possible to distinguish between early 
and late apoptotic cells, since the first ones could be only stained with Annexin V (Fig.12A) 
while the second with both Annexin V and 7-AAD (Fig.12A). According to the 
ImageStream® analysis both apoptotic and necrotic events occurred, but while about 40% 
(39.4±4.7%, Fig.12B) of the cells did undergo necrosis already after 6 hours DCF exposure, 
only obout 10% of them were either early (4.6±0.7%, Fig. 18C) or late apoptotic (6.8±0.4%, 
Fig.12D), after 6 hours DCF exposure. After 24 hours about 50% of the cells were instead 
either early (21.1±3.8%, Fig. 18C) or late apoptotic (28.2±2.3%, Fig.12D). This observation 
agrees with previous works that show how necrotic events generally occur earlier than 
apoptotic ones after cell exposure to toxic hazards [106, 107]. However, we believe that the 
real percentage of dead cells in the DCF treated samples would be greater, since we only took 
into account the cells that were still adherent, which are the same analyzed by FLIM. Finally, 
about 20% of dead cells could be found already in the control (20.8±2.2% and 25.1 ±2.3% 
after 6 and 24 hours, respectively, Fig.12B) mainly because of being out of the incubator 
during the FLIM measurements as well as by preparing the samples for the ImageStream® 
analysis. Besides, also the chosen cell harvesting method could affect the results of the 
analysis leading to an overestimation of the necrotic cells [108]. Nevertheless, the percentage 
of the apoptotic (either early or late) and of the total dead cells was significant higher in the 
treated samples when compared to the control, both after 6 (Fig.12B, DCF treated: 50.8±5.3% 
versus CTRL: 20.8±2.2%, p=0.008) and 24 hours (Fig.12B, DCF treated: 56.7±5.6% versus 
CTRL: 25.1 ±2.3%, p=0.007). 
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Fig.12. ImageStream® analysis of HDFs exposed to a DCF-loaded PLA scaffold. A. Staining 
with Annexin V (blue) and 7-AAD (red) allowed us to distinguish among healthy (blue-;  
red-), necrotic (blue-; red+), early (blue+; red-) and late (blue+; red+) apoptotic cells. B-D. 
Data analysis of the cells after staining and counting (CTRL: green stripes; DCF treated: red 
dots): total percentage of dead cells (B); early (C) and late (D) apoptotic cells percentage. 
 
2.2.4. MPM and FLIM real time analysis  
Since we could find a strong significant change in both α1 (%) and τ1 values, as well as in the 
cell morphology of HDFs, already after 6 hours incubation together with a DCF-loaded 
scaffold, we decided to analyze the treated cells over the first 6 hours exposure too. Using a 
IBIDI® heating system we analyzed always the same cells with MPM and we could image the 
morphological change due to the induced cell death (Fig.13 A-L).  
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Fig.13. MPM imaging of HDFs exposed to a DCF-loaded PLA scaffold for 5 hours. Dish was 
kept by 37°C using a IBIDI® heating system that suited the microscope and the same cells 
were imaged every 20 minutes for the first 140 minutes (A-H) and then every 40 minutes (I-
L). Scale bar equals 50µM. 
Cells were imaged every 20 minutes (after 140 minutes images are shown every 40 minutes 
since no morphological differences could be detected every 20 minutes after that time). 300 
minutes (Fig.13L) represented the last point since after 5 hours the analyzed cells were 
detached and appeared out of focus (images not shown). Separetely, we performed a FLIM 
analysis of DCF-exposed cells over the first 6 hours too. By fitting the FLIM values with a 
linear regression (Fig.14) we could find a linear increase (R
2
=0.998) of the τ1 values over the 
first 6 hours (Fig.14A) and a linear decrease for the α1 (%) values (Fig.14B), even if the 
regression coefficient was in the second case worse (R
2
=0.973). 
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Fig.14. Linear regression fitting for the τ1 (A) and α1% (B) values of HDFs exposed to a DCF-
loaded PLA scaffold for 6 hours.  
τ1 values significant increased already after 90 minutes DCF exposure (τ1 (t=0): 649±4 ps 
versus τ1 (t=90 minutes): 672±5 ps, p=0.0031, Fig.14A), while the α1(%) significantly 
decreased first after 3 hours (α1% (t=0): 70.4±1.6% versus α1% (t=180 minutes): 64.2±1.3% 
ps, p=0.0016, Fig.14B). The better linear regression found by analyzing the τ1 values 
(R
2
=0.998, Fig.14A) in comparison to the one obtained for α1% (R
2
=0.973, Fig.14B) could be 
probably because the first refers to changes in the microenvironment, that is cell independent 
[109, 110], while the second to metabolic ones [110].  
 
2.3. Discussion 
Improved in vitro models are required to aid scientists in identificating and investigating 
candidate molecules for pharmaceutical development [111]. It is to time well accepted 
especially in the European Union that in vitro models will not be able to replace animal 
testing in the next future [111-113]. However, the scientific community agrees that animal 
studies are expensive, and it would be desirable to minimize this necessary part of drug 
testing, also because of the associated ethical issues [114-116]. In vitro studies are generally 
less expensive, faster and more flexible than regulated in vivo tests [111]. Nevertheless, the 
limited reliability and in vivo reproducibility of existing in vitro tests place great emphasis on 
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the need for more realistic models. Over the last decades, many investigators have been 
researching on in vitro assays that should enable informed strategic decisions already during 
screening processes, thus avoiding entire animal testing [113]. One of the biggest limits of the 
nowadays available in vitro systems by assessing the toxicity of drugs is the necessity to work 
with specific concentrations of the investigated substance. This approach is good to assess 
dangers and risks related to the hazards, but it doesn’t really reproduce the therapeutic 
situation [111]. Controlled delivery over time can in this way better mimic the drug 
bioavailability after its administration, and can also help to reproduce the real daily dosages. 
Nano-delivery systems represent a great future perspective in this field, and are gaining a 
constantly growing interest among scientists [117]. In this thesis, we could effective 
encapsulate DCF in a PLA electrospun scaffold, finally having a system that allowed us to 
obtain a controlled drug delivery over 24 hours. Furthermore, we were able to enhance the 
initial release of DCF from our system by simply adding DMSO without changing neither the 
DCF content in the scaffold nor the drug-release profile. According to our results we believe 
that the encapsulated DMSO rapidly diffuses from the PLA scaffold carrying DCF as well. 
The effectiveness of the DCF/DMSO encapsulation and their subsequent release were proved 
by parallel using different analyses. The effective release of DCF from the electrospun 
scaffolds (either containing DMSO as well or not) was firstly proved with RP-HPLC. Besides, 
we investigated the release mechanism using Peppas equation, which offers a simple model to 
study drug-release mechanisms [37, 38], also from electrospun scaffolds [96, 97]. According 
to the obtained experimental release exponent the drug undergoes a controlled diffusion from 
the electrospun scaffolds [38]. Interestingly, the addition of DMSO doesn’t alter the drug 
diffusion mechanism but only enhances the initial burst release of DCF. Nevertheless, the 
fibrous morphology of the scaffold appears clearly altered according to SEM observations, 
when having DMSO in the electrospun materials. The DMSO containing fibers seem 
crosslinked or merged [118]. However, no beads formed and the structure still appears 
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homogeneous. Moreover, after the release experiments, the DMSO containing samples 
regained the fibrous structure typical of electrospun scaffolds. The changes in the scaffolds 
morphology were related to the encapsulation of DMSO and its subsequent release according 
to our observations. To confirm our hypothesis we proved DMSO and DCF encapsulation 
with EDX, and their release with 
1
H-NMR and EDX as well. EDX analysis has already been 
employed to investigate the elemental composition of electrospun scaffolds [119]. In our case, 
we used pure PLA as polymer, a polyester composed of only Carbon (C), Hydrogen (H) and 
Oxygen (O). On the other side, DMSO contains Sulphur (S) as well, while DCF Sodium (Na) 
and Chlorine (Cl). Thus, we could correlate the presence of DMSO with the presence of S 
peak on the EDX spectrum, and Cl and Na signals to the effective DCF encapsulation. 
Interestingly, after the release experiment (24 hours PBS immersion) only C and O signals 
could be detected from all the scaffolds, suggesting the diffusion of both DMSO and DCF 
from the starting functionalized materials, with a final content lower than 10% in weight, due 
to EDX detection limits [120]. Besides, with 
1
H-NMR we could also demonstrate that DCF 
and DMSO were released unmodified from the electrospun scaffolds. This analysis was in our 
opinion necessary to prove that the encapsulated molecules effectively undergo a diffusion 
and not degradation or modification during the whole processing. This aspect is particularly 
important in this part of the thesis, since our final purpose was to prove DCF cytotoxicity 
towards HDFs. Before investigating the effects of DCF on HDFs, we characterized the 
mechanical properties of the electrospun scaffolds. We observed that the DCF encapsulation 
strongly affected scaffold elasticity, since the DCF containing electrospun scaffolds showed a 
much higher Young’s modulus, as well as a lower elongation at break, than the ones not 
containing it. On the other hand, the hydrophobicity of the scaffolds was not affected when 
having DMSO and/or DCF, since the contact angle of all the modified scaffolds was not 
significant different when compared to pure PLA. After having characterized the mechanical 
properties of the scaffolds, we could demonstrate that cytotoxic effects were related to the 
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diffusion of the unmodified DCF according to the results of an accredited MTS assay. Instead, 
the presence of DMSO in the scaffolds did not affect PLA biocompatibility, probably because 
of its low amount [103-105]. This result is interesting, and suggests that DMSO could be 
effectively encapsulated in electrospun scaffolds to tune their properties, and enhance drug 
diffusion from the delivery systems. According to our idea, the drug-loaded scaffolds can be 
used as models to mimic the daily dosage, ensuring controlled drug diffusion over 24 hours. 
We believe that electrospinning offers in this way a broad spectrum of possibilities to 
encapsulate different drugs and ensure their controlled diffusion [3]. In the final part, thanks 
to MPM coupled with FLIM, we could analyze HDFs exposed to DCF and assess drug 
toxicity. A well-recognized effect of high concentrations of DCF is rapid and concentration-
dependent cellular energy depletion [76]. Masubuchi et al. [76] have demonstrated that a 
relevant ATP depletion occurs in rat hepatocytes, when exposed to high DCF concentration 
(up to 100 µM). The ATP depletion is almost complete when working with DCF 500 µM 
[76]. Drug-induced oxidative stress can primarily recruit rescue pathways, but, if sustained, 
the stress can cause mitochondrial injury [80, 81]. Thus, the cells are usually not able anymore 
to repair the damage, and apoptotic or necrotic events mainly occur [82-84]. In this thesis, 
using MPM we could image changes in the morphology of the treated HDFs that allowed us 
to distinguish between necrotic and apoptotic cells [66, 123]. DCF induced cell death could be 
imaged even live over 5 hours, always analyzing the same cells. These morphological 
observations were confirmed with ImageStream® [92]. According to these data, we could 
prove that both apoptotic and necrotic events occurred in HDFs, when exposed to DCF. 
Besides, the FLIM analysis showed us changes in the cell metabolism of HDFs after DCF 
exposure, in terms of decrease in the contribution of free NAD(P)H (α1%) to the glycolytic 
activity. At the same time the fluorescence lifetime of free NAD(P)H (τ1) significantly 
increased. Free NAD(P)H is mainly located in the cytoplasm [124]. Thus, we believe that the 
significant change in its fluorescence lifetime is mainly to attribute to the changes in its 
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microenvironment, since especially in the necrotic cells the cytosol content is released after 
the disruption of the cell membrane [123]. The use of MPM coupled with FLIM by cell 
imaging and analysis, together with the choice of electrospun scaffolds as substrates for the 
drug delivery, could offer a new marker-free, not destroying method for the in vitro 
investigation of effects and mechanism of action of drugs. Actually, using this experimental 
setup we were able to image DCF induced cell death in HDFs thanks to MPM and analyze 
changes in the cell metabolism using FLIM. As a perspective, the here proposed model could 
be extended to longer studies where each 24 hours (or at specific time points) the target cells 
can be supplied with new culture medium and a new drug-loaded scaffold containing the 
desired drug amount. A big limit of many already existing in vitro systems is that the cells get 
damaged or die directly after the analysis, and so cannot be monitored over time [121]. Using 
MPM and FLIM, we were instead able to image and analyze the (same) cells at different time 
points. This aspect is of great interest since the here used approach could allow in vitro 
analysis over a long time that can represent, for example, the expected whole therapy in case 
of having adequate cell culture systems [122]. In the next future we aim to use the here 
proposed in vitro model also with other drugs and different cell lines in order to assess its 
reliability, and find new possible application fields. Furthermore, we aim to use the same 
setup with in vitro skin models instead of HDFs. These models would better represent the in 
vivo behavior than monolayer cell cultures. Moreover, we aim to further investigate how the 
use of DMSO affects the morphology and the drug-release profile of electrospun scaffolds. In 
particular, our challenge would be to find out if they can be predicted and controlled, by for 
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In this part of the thesis we were able to effectively encapsulate DCF in a PLA scaffold, 
producing a system that allowed us to obtain a controlled drug release over 24 hours. HDFs 
were incubated together with the DCF-loaded electrospun PLA scaffold and then imaged with 
MPM. According to the observed morphological changes and the ImageStream® analysis, 
DCF trigger both apoptosis and necrosis in HDFs. Besides, metabolic changes in the treated 
cells were detected using FLIM. The model here proposed is marker-free and not destroying, 
and could represent a new interesting perspective for the in vitro testing of drugs or hazards. 
Moreover, we proved that the use of DMSO as co-solvent of HFIP alters the properties of 
electrospun PLA scaffolds. We found out that DMSO cannot be completely evaporated during 
the electrospinning process and remains retained within the fibers. Thus, the fiber size 
increases and this leads to lower tensile strength and E-modulus for the scaffold. However, 
after water immersion, DMSO diffuses and the fibers regain their normal morphology. When 
encapsulating DCF too, DMSO enhances its initial burst release from the PLA scaffold. These 
results suggest that DMSO could be used in small volumes as a co-solvent by electrospinning 
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CHAPTER 3. PRODUCTION AND CHARACTERIZATION OF AN ELECTROSPUN 
PLA SCAFFOLD LOADED WITH A SYNTHETIC DICLOFENAC PRODRUG FOR 
THE LOCAL TREATMENT OF ACTINIC KERATOSIS 
3.1. Introduction 
The medical term “actinic keratosis (AK)” identifies small skin lesions, which appear as 
round, rough spots between 5 mm and 1 cm in diameter. AKs are characterized as pre-
cancerous or as early-stage tumors [125, 126]. This pathology is also known as "solar 
keratosis" or "senile keratosis" because it is more common to people over 50 with fair skin 
and is related to a prolonged sun-damage [125]. This process, also known as photoaging, 
leads to an accumulation of oncogenic changes [126]. Changes related to photodamage are 
most evident in the extracellular matrix (ECM) [127]. The accumulation of these changes 
leads to a pathological ECM mainly due to the degradation and fragmentation of its 
components such as elastic fibers [128]. As a result, the normal repair and regenerative 
capacity of the ECM is inhibited [128-130]. Skin ageing processes also have a significant 
impact on cellular mechanisms such as DNA repair, gene expression and immune response 
modulation [129]. AK is considered a key event in the progression from photoaged skin to the 
invasive squamous cell carcinoma (SCC) [43, 126]. SCC affects the keratinocytes of the 
epidermis layer and is the second most diffused skin cancer after the basal cell carcinoma 
(BCC) [125, 131]. However, there are many more AKs than SCCs and it is difficult to predict 
exactly which lesions will progress to invasive cancer [125, 126]. About 15% of the men and 
6% of the women in Europe are affected by AKs. The percentages rise respectively to 34% 
and 18% in the European population over 70 years of age [131]. Since the average life 
expectancy is increasing, it is predicted that even more people will be affected by AKs in the 
next years [125, 126]. Although a number of treatments are already available [132-134], the 
development of effective, more targeted and well-tolerable therapies for the treatment of AKs 
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is still of great interest. The first therapy approved by the Food and Drug Administration 
(FDA) for the topical treatment of AKs was 5-Fluorouracil in 1962 [132] followed by 
Imiquimod in 1997 [132], Diclofenac sodium salt (DCF) in 2002 [133, 134] and Ingenol 
Mebutate in 2012 [134]. Among them, DCF is currently the therapy of choice in terms of 
costs, effectiveness, side effects and tolerability [135]. Diclofenac belongs to the class of non-
steroidal anti-inflammatory drugs (NSAIDs) and is one of the most commonly used in the 
world [135]. It is still not clear how DCF affects AKs, but its activity seems to be related to 
anti-inflammatory and anti-angiogenic effects [136]. Induced apoptosis has been also 
proposed as a possible DCF mechanism of action in the treatment of AKs [137]. The 
absorption of a drug through the outermost layer of the skin, the stratum corneum (SC), is 
limited [138]. Thus, a specific formulation of DCF commercially known as Solaraze® is 
needed for the effective treatment of AKs. This formulation is supplied with hyaluronic acid 
that enables DCF accumulation in the epidermis [139]. Considering these aspects, a chemical 
modification of Diclofenac that enhances its permeation through the SC is of interest since it 
could improve its efficacy against AKs. 
Over the last two decades, electrospinning has gained growing interest as a potential polymer 
processing technique for applications in tissue engineering [140, 141] and drug delivery [3]. 
Electrospinning is an easy way to fabricate fiber-containing scaffolds with a fiber diameter in 
the nano- to micrometer size scale that mimic the structure and morphology of the ECM 
components in the skin [140-142]. Biodegradable and natural materials can be electrospun, 
and a wide range of molecules like drugs and proteins can be incorporated in the scaffolds [3]. 
Polylactic acid is a biodegradable, biocompatible polymer with beneficial mechanical 
properties. Moreover, it is stable over a long time and its degradation proceeds through the 
hydrolysis of the ester linkage in the polymer’s backbone resulting in a non-toxic degradation 
product called lactic acid [143, 144].  
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In this study, we aimed to encapsulate a chemical modified and synthetically produced 
Diclofenac prodrug in an electrospun poly-L-lactide (PLA) scaffold in order to obtain a 
suitable drug delivery system to locally treat AKs. Specifically, the prodrug was successfully 
synthesized by binding Diclofenac to a glycine residue via solid phase peptide synthesis 
(SPPS) and then incorporated in an electrospun PLA scaffold. The drug encapsulation was 
verified using multiphoton microscopy (MPM) and its release was monitored 
spectrophotometrically and confirmed with MPM as well. The scaffold was further 
characterized with scanning electron microscopy (SEM), tensile testing and contact angle 
measurements. Its biocompatibility was verified by performing a cell proliferation assay and 
compared to PLA scaffolds containing the same amount of DCF. Finally, the effect of the 
electrospun scaffolds on human dermal fibroblasts (HDFs) morphology and metabolism was 
investigated by combining MPM with fluorescence lifetime imaging microscopy (FLIM). The 
obtained results suggest that the obtained scaffold could be suitable for the controlled and 
targeted delivery of the synthesized prodrug for the treatment of AKs. A controlled and 
targeted drug delivery to the region of interest could reduce the undesired side-effects and 
enhance the efficacy of the therapy. The work described in this chapter and its final goal are 
schematized in Fig.15. 
 
Fig.15. Graphical description of the production and characterization of the drug-loaded 
electrospun PLA scaffolds and their final application. 
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3.2.1. Synthesis of a Diclofenac prodrug via SPPS 
The DCF-Gly derivative was chosen according to the predicted values for its MW (=353.20 
g/mol) and logP (=2.78), which were estimated using Molinspiration®, making it suitable for 
a transdermal delivery [138]. The synthetic scheme used for the DCF-Gly synthesis is shown 
in Scheme 5. The desired product was obtained with a high degree of purity (99%) according 
to NMR analysis (Fig.S6A, S6B) and was recovered in a high yield (98%). 
 
Scheme 5. Synthesis of DCF-Gly via SPPS with H-Gly-2ClTrt Resin 
The final product was also characterized by MALDI-MS (Fig.S6C).  
 
3.2.2. Production of the scaffolds by electrospinning 
PLA was dissolved in HFIP either alone or in presence of DCF-Gly or DCF. Various 
electrospinning parameters were tested and those leading to a stable Taylor’s cone and jet as 
well as to smooth and uniform fibers were then used throughout the study. The conditions 
were first defined for pure PLA and then adapted for the drug-loaded scaffolds.  
 
3.2.3. SEM and fiber diameter analysis 
Morphology and fiber size of the PLA scaffold and of the DCF-Gly loaded scaffold, before 
and after drug release (a.r.) were investigated using SEM (Fig.16). It was possible to generate 
scaffolds with a random fiber orientation. In all conditions, we obtained uniform nanofibers 
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with no beads (Fig.16 A-F). After drug release, morphological changes were visible; however, 
the fibers were still uniform and randomly oriented (Fig.16 G-I). Fiber sizes significantly 
increased by the incorporation of the drug (PLA: 148±9 nm versus PLA + DCF-Gly: 180±9 
nm; p=0.001). Despite the change in morphology, there was no significant decrease in fiber 
size after drug release (PLA + DCF-Gly: 180±9 nm versus PLA + DCF-Gly a.r.: 170±8 nm; 
p=0.48). 
 
Fig. 16. Analysis of the morphology and fiber size of the electrospun scaffolds. A-F. SEM 
images of the electrospun scaffolds at different magnifications (a.r. = after release; scale bars: 
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3.2.4. Contact angle measurements 
Wettability of the scaffolds was determined using contact angle measurements (Fig.17 A-B). 
The analysis showed that the drug-loaded scaffolds remained highly hydrophobic (PLA + 
DCF-Gly: 130.1±8°) and no significant changes (p=0.81) were determined when compared 
with the pure PLA scaffolds (PLA: 131±7°). 
 
Fig.17. Analysis of the physical properties of the electrospun scaffolds. Drop shape analysis 
of the pure PLA (A) and the DCF-Gly containing PLA (B) scaffolds after water deposition. 
Representative stress-strain curves for pure PLA (C) and PLA + DCF-Gly (D). 
 
3.2.5. Tensile tests 
PLA is an elastic and electrospinnable polymer. No significant differences were observed in 
regards to tensile strength (PLA: 1.84±0.19 MPa [88] versus PLA + DCF-Gly: 1.91±0.18 
MPa; p=0.67) and Young’s modulus (PLA: 24.4±9.7 MPa [88] versus PLA + DCF-Gly: 
25.4±1.2 MPa; p=0.48) when comparing the pure electrospun PLA with the drug-containing 
scaffold. Like the hydrophobicity, the elastic modulus and tensile strength were not influenced 
by the encapsulation of DCF-Gly. The experimental curves obtained for the PLA and the PLA 
+ DCF-Gly scaffolds are shown in Fig.17C and 17D, respectively. 
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3.2.6. MPM analysis 
MPM of the synthesized prodrug was employed for the visualization of the drug 
encapsulation profiting from the presence of an aromatic ring on the DCF molecule. Whereas 
there was no signal detectable for pure PLA scaffolds (Fig.S7), a strong signal was obtained 
for the drug-loaded PLA + DCF-Gly scaffolds (Fig.18A) demonstrating that drug 
encapsulation with electrospinning was successful. Furthermore, multiphoton laser-induced 
autofluorescence signals were detected from the entire scaffold. Every fiber is clearly visible, 
confirming that DCF-Gly is homogeneously distributed throughout the scaffold and the single 
fibers. After drug release, the signals significantly decreased or were absent (Fig.18B). Only a 
few fibers of the scaffold could be visualized suggesting that most of the encapsulated drug 
had been successfully released from the scaffold after the incubation in PBS. The obtained 
mean gray values (Fig.18C) were 82±12 and 8.1±1.1 before and after the drug release, 
respectively. According to these values the percentage of the not released drug was estimated 
to be approximately 10%. 
 
Fig.18. MPM imaging of the DCF-Gly loaded scaffolds. MPM images (scale bars=10µm) of 
the DCF-Gly loaded scaffold before (A) and after (B) the drug release. Gray values intensities 
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3.2.7. Drug release experiments 
After demonstrating that the drug was successfully encapsulated within the PLA fibers, the 
ability of the scaffold to release the drug was investigated. The absorbance at 272 nm of the 
PBS solution, in which the scaffold was immersed, was constantly monitored for the first 7 
hours (Fig.19A). Thereafter, it was measured again after 24, 48 and 72 hours. The absorbance 
value was constant after the first 24 hours. This time was therefore set as the end point 
measurement. According to a calibration curve and assuming that no loss of the drug occurs 
during the electrospinning process we could estimate that 89±2% of the encapsulated drug 
was released from the scaffold after 24 hours, which agrees with the results obtained by the 
GVI analysis of MPM images (Fig.18). The obtained data were also plotted in a logarithmic 
form (Fig.19B) using the equation developed by Peppas et al. [37], that offers a simple model 
to study the release mechanism of incorporated molecules from polymers. According to the 
value obtained for the slope (0.29±0.03), which is lower than 0.45, Peppas model suggests 
that drug-release undergoes a controlled diffusion [38]. 
 
Fig.19. Release profile of DCF-Gly from the PLA scaffold. Drug release analysis (A) and 
logarithmic fitting of the drug release data with Peppas equation (B). 
The effectiveness of the release of DCF-Gly from the PLA scaffold was verified by RP-HPLC 
too (Fig.S8A and S8B). A binary gradient of CH3CN/ddH2O from 5 to 70% over 30 minutes 
(540% over the first 10 min followed by 4050% over the next 15 min and 5070% over 
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the last 5 min) was used allowing a good separation for pure DCF-Gly in PBS (retention time: 
18 min by 45.3% CH3CN/ ddH2O, Fig.S8A). The same conditions were then used also for the 
elution of the supernatant of the drug-loaded scaffold extract in PBS. The unmodified DCF-
Gly released from the PLA scaffold could be eluted with a high degree of purity (Fig.S8B). 
 
3.2.8. In vitro cytotoxicity 
The biocompatibility of the modified scaffold was assessed with a MTS assay using a 
standardized protocol and HDFs (Fig.20E). A material is non-cytotoxic when the proliferation 
is higher than 80% relative to the NC [145]. Accordingly, we determined that the PLA 
scaffolds, either with or without the encapsulated DCF-Gly, showed no cytotoxic effects (cell 
proliferation: PLA = 104±6%; PLA + DCF-Gly = 105±7%). The assay was also performed 
with a PLA scaffold containing the unmodified DCF as a positive cytotoxic control [146]. In 
this case, a severe cytotoxicity (cell proliferation = 16±3% versus NC, p=5e
-6
) was observed. 
 
3.2.9. FLIM analysis 
FLIM was performed to analyze endogenous NAD(P)H in HDFs as a measure for metabolic 
changes in the target cells due to the incubation together with the drug-loaded scaffolds. For 
FLIM analyses, a biexponential decay was employed assuming to have two different 
fluorescence lifetimes for the free (τ1) and the protein-bound (τ2) NAD(P)H [42], respectively. 
The α1 (%) represents the free NAD(P)H relative contribution to the final lifetime values. 
Moreover, we aimed to correlate the obtained data directly with the results that arose from the 
MTS assay since the rate of tetrazolium reduction reflects the general metabolic activity/rate 
of glycolytic NAD(P)H [41]. No changes in the cell morphology could be observed for the 
DCF-Gly loaded and pure PLA scaffolds when compared to the controls (Fig.20 A-C). The 
cells were elongated and showed the typical shape of fibroblasts [147].  
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However, when exposed to DCF, a significant morphological change was observed in the 
MPM images (Fig.20D) due to induced necrosis / apoptosis [147]. Here, the cytoplasm and 
the nucleus were clearly altered. This morphological change correlated to a metabolic change 
according to the α1% values of FLIM measurements. A significant decrease in the free 
NAD(P)H level (α1 (%); Fig.20F) was observed for the PLA + DCF treated HDFs when 
compared to the control (NC), but not for PLA or PLA + DCF-Gly exposed cells (PLA + 
DCF: 63.9±0.9% versus NC: 67.5±0.8%; p=0.001). No significant changes in τ1 and τ2 were 
detectable (Fig.S9). 
 
Fig.20. Cytotoxicity assessment using HDFs. MPM images of HDFs (A-D). HDFs treated 
with cell culture medium only as negative control (A) or in presence of PLA (B), PLA + 
DCF-Gly(C) and PLA + DCF (D) scaffolds. Scale bars equal 20 µm. Results of the accredited 
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Three dimensional scaffolds are of growing interest among scientists for applications in the 
field of tissue engineering or as drug delivery systems [148, 149]. Among the currently 
employed polymers, polylactide may be the most suitable material for the production of 
slowly biodegradable scaffolds for biomedical applications [150]. Thus, polylactide is also a 
suitable material to produce systems for a controlled drug delivery [151]. DCF is one of the 
most potent NSAIDs [152, 153]. It has been used for the treatment of many different diseases 
such as osteoarthritis [154] and AKs [155, 156]. Since its approval, a number of different 
DCF containing products have been developed with the goal of improving efficacy, 
tolerability, and patient convenience [157-160]. However, no new formulations of DCF for 
the treatment of AKs have been proposed since its FDA approval in 2002 [133]. The 
Diclofenac formulation proposed in this thesis should offer a new option for the local 
treatment of AKs. DCF has unique chemical features. For example, the amine function is a 
very weak base when compared to other secondary amines [161]. This feature was utilized in 
this study to handle Diclofenac as an amino acid analogue with protected amine function in 
SPPS. In particular, it was linked to a glycine residue by forming an amidic bond to obtain a 
derivative (DCF-Gly) with a lower logP when compared to DCF (estimated logP: DCF-Gly= 
2.78 versus DCF= 4.96). This is necessary in order to be suitable for a transdermal delivery 
[138]. The formation of an amidic bond is a well-used strategy for the synthesis of prodrugs 
since it may be easily cleaved by enzymatic hydrolysis [162, 163]. Solid phase synthesis 
represents a clean, versatile and efficient way to avoid the use of large amounts of solvents 
and reagents [163]. Amide prodrugs of DCF have already been synthesized by Kumar et al. 
[164]. However, the synthetic scheme that was proposed allowed them to reach only yields 
about 60% [164]. Here, we obtained a quantitative yield of 98%. Moreover, we obtained the 
free amino acid derivative instead of the protected ester [164], which is crucial when aiming 
for obtaining a synthesized prodrug with proper hydrophobicity. For the synthesis of the DCF-
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Gly prodrug, a 2-Chloro Trityl Chloride (2-CTRL-Cl) resin was employed. The 2-CTRL-Cl 
resin allows the synthesis of peptides with a carboxylic group at the C-terminus [165], and is 
compatible with the Fluorenyl-9-methoxycarbonyl protecting group chemistry [166, 167]. 
Compared to the other resins, the 2-CTRL-Cl one has not only the advantage to produce 
peptides free from diastereomeric side-products [165-167], but offers the possibility to operate 
the cleavage under mild acidic conditions (either 1% TFA/DCM [166] or AcOH/TFE/DCM 
[167]), which is required when handling protected or modified peptides. The opportunity of 
binding DCF to different amino acid residues and even to longer peptide chains without the 
need of further purification could be employed to obtain many different DCF derivatives. This 
is potentially very useful considering the variety of medical applications of DCF [152-155]. 
The results obtained in this study by binding Diclofenac to a glycine residue are promising 
since we achieved a high yield and a great degree of purity. However, the versatility of this 
synthesis has to be further investigated. The synthesized DCF-Gly prodrug was successfully 
incorporated in a PLA scaffold using electrospinning. The obtained electrospun scaffold was 
then characterized in order to demonstrate that it is a suitable system for the topical treatment 
of AKs. In particular, the morphology of the scaffold was investigated using SEM. This 
technique is the often used for the investigation of nanostructures. It is reliable and allows 
high magnifications with a good resolution [168]. Thus, this analysis was necessary to 
investigate the scaffold morphology, analyze the diameter distributions and compare them. 
The SEM investigation showed a homogeneous fibrous structure of the generated electrospun 
scaffolds. For the drug-loaded scaffolds, a significant increase in the fiber diameters could be 
observed. This may be due to the increase in viscosity of the electrospun solution and also the 
presence of the drug molecules within the polymeric fibers [169]. Nevertheless, the mean 
values of the fiber diameter remained still lower than 200 nm, and a regular fibrous structure 
with no beads was maintained. The increased fiber diameters after drug encapsulation did not 
affect the mechanical properties such as the Young’s modulus or the tensile strength of the 
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electrospun scaffold. Soliman et al. [170] and Milleret et al. [171] showed in previous studies 
that fiber diameter and orientation, as well as scaffold porosity can impact the mechanical 
properties of the scaffolds. In particular, they both proved that an increase in the fiber 
diameter leads to a significant increase in the Young’s modulus [170, 171]. However, they 
analyzed differences in the diameter values that were in the µm range [170, 171]. In our case 
the variation in the fiber diameters is probably too low to significantly impact the investigated 
mechanical properties. By adding DCF-Gly, the wettability of the scaffolds was also not 
affected. The scaffolds remained highly hydrophobic as it is described for pure PLA [141]. 
We have chosen PLA as the drug carrier, since hydrophobicity is important to ensure the drug 
diffusion from the scaffold into the lesion [172, 173]. DCF-Gly encapsulation could be easily 
visualized using MPM due to the ability to selectively induce DCF autofluorescence [174]. 
One of the advantages of the MPM technique is the ability to image non-invasively and thus 
without destroying or modifying the samples [175, 176]. This enables a simple, in situ quality 
control. MPM has already been used to image scaffolds with and without a fibrous structure 
[177, 178]; however, a good contrast or resolution could not be achieved thus far. 
Interestingly, we obtained a good contrast using a very low laser power (3.2mW). This 
approach is promising and could be potentially extended to different substrates since a great 
number of drugs and endogenous molecules are autofluorescent when excited at defined 
wavelengths. Here, we used MPM to show successful encapsulation and release of the 
prodrug. By calculating the GVI, it was possible to estimate the amount of non-released DCF-
Gly. After 24 hours, 10% of DCF-Gly remained in the scaffold, which is comparable to values 
from literature described by Sidney et al. for previously developed DCF eluting systems 
[158]. However, the initial burst release was ~ 60% [158], and in our study only ~20%. Initial 
burst of drug release is related to drug type, drug concentration, polymer hydrophobicity and 
scaffold nanostructure [179-181]. In contrast to the previously described eluting system, the 
one described in this study utilized a fibrous structure since it was obtained via 
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electrospinning. Moreover, hydrophobic PLA was used as the only polymer while Sidney et 
al. used a mixture of the hydrophobic polyester PLGA (poly-lactic-co-glycolic acid) with the 
more hydrophilic PEG (poly-ethylene glycol) [138]. In addition, the synthesized DCF-Gly 
prodrug was used as free acid instead of the Diclofenac sodium salt (DCF). Carboxylic acids 
have lower water solubility than the correspondent sodium salts, thus showing a slower and 
more controlled diffusion over the time [182]. Due to these features, the formulation that is 
proposed here helps to reduce the initial burst release and to have a sustained drug diffusion 
from the scaffold over the first 24 hours. Furthermore, we investigated the amount of the 
released drug in the supernatant. It has been shown before, that drug release can be controlled 
and influenced by changing various parameters such as hydrophobicity, fiber size or drug 
concentration [183]. The encapsulated DCF-Gly was effectively released from the scaffold 
following a controlled diffusion according to the spectrophotometric measurements and the 
Peppas equation. This equation has already been employed as a simple model to investigate 
the drug release from electrospun scaffolds [183-185]. For the here characterized scaffold, the 
release mechanism undergoes a controlled diffusion due to a very low release exponent of 
0.29. The encapsulated drug is mostly (~90%) released within the first 24 h. Such a behavior 
is suitable for the aim of this thesis considering that DCF is used as a daily treatment to cure 
AKs [134]. Furthermore, the in vitro biocompatibility of the drug-containing scaffold was 
tested by performing a MTS cell proliferation assay. This test allows for a quantitative 
evaluation of cytotoxicity [183] and satisfies the international standard requirements of ISO 
10993-5. In contrast to DCF, DCF-Gly was non-cytotoxic, after release from PLA scaffolds. 
It is well known that DCF induces cell death [146, 187], suggesting that the newly 
synthesized molecule is a promising non-cytotoxic prodrug for treating AK. In addition, we 
investigated the effect of DCF on HDFs after its release from the PLA scaffold employing 
MPM coupled with FLIM. For the analysis NAD(P)H was chosen as a target [42]. This 
approach allows the monitoring of changes in cell morphology and metabolism without the 
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need of staining or the interruption of cell culture. The MPM analysis allowed us to image 
morphological changes in HDFs after the DCF treatment. It is known that DCF induces cell 
death due to a mitochondrial injury [184]. Specifically, either apoptosis or necrosis is induced 
depending on how many mitochondria are affected [146]. In this thesis we aimed to correlate 
the observed morphological changes to the induced cell death as previously described by 
Seidenari et al. [147]. In particular, cells that showed a nuclear and cytoplasmic condensation 
were assessed as apoptotic while cells showing both swelling and vacuolation of the 
cytoplasm were considered to undergo necrosis [147]. According to the morphological 
observations obtained with MPM, we suggest that both apoptotic and necrotic events occur 
after the DCF treatment. Besides, FLIM allowed the detection of metabolic changes after the 
DCF treatment. In particular, a significant decrease in the rate of glycolytic NAD(P)H [42] 
could be detected. FLIM data supported the results obtained from the MTS assay. Our results 
show that employing a drug-loaded PLA scaffold as a drug-releasing wound dressing to treat 
AKs could be a very useful and promising alternative to current treatment strategies. It would 
help to control the daily dosage, thus significantly reducing side-effects, and be applicable as 
targeted therapy. In addition, the here proposed formulation could be very useful after surgical 
procedures, photodynamic- and cryotherapy because it would ensure a protection of the 
treated area and favor the wound healing [188-190]. It has been reported that the application 
of drug-free electrospun PLA nanofibrous scaffolds as wound dressing materials already 
enhance the recovery process [190-193], indicating that the here presented combination of 
PLA and DCF-Gly is a highly interesting candidate for AK treatment. In order to confirm an 
enhanced transdermal delivery of the synthesized DCF-Gly prodrug compared to DCF [194], 
further experiments are necessary. Particurarly, the effective DCF-Gly absorption through the 
skin and its activation by enzymatic hydrolis have to be verified [195]. 3D in vitro skin 
models would offer a closer to in vivo system to test these aspects compared to monolayer cell 
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cultures [196]. Finally, the effectiveness to treat AK needs to be further investigated in 
adequate in vivo models.  
 
3.4. Conclusions 
In this study, an electrospun PLA scaffold loaded with a synthetically obtained DCF prodrug 
was generated and characterized. The proposed DCF-Gly synthesis based on the use of SPPS 
is novel and promising. Compared to unmodified DCF, DCF-Gly is non-cytotoxic and 
therefore potentially a more suitable drug to treat AK. The electrospun PLA + DCF-Gly 
scaffold represents an interesting drug releasing system that enables a controlled and targeted 
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CHAPTER 4. HYBRID GELATIN/POLYLACTIDE ELECTROSPUN SCAFFOLDS 
WITH CONTROLLED HYDROPHOBICITY AND WETTABILITY 
4.1. Introduction 
Blend nanofibrous electrospun scaffolds represent an emerging class of nanostructures that 
can mimic the native tissue, and besides interact with the local microenviroment [197-199]. 
By combining two or more polymers, they can behave cooperatively to finally provide hybrid 
scaffolds with unique mechanical, biochemical and structural properties [200]. Blend 
electrospun scaffolds have already found application in a wide range of tissue engineering and 
drug delivery systems [198, 201]. To this end, many scientists have already demonstrated that 
nanofibrous scaffolds are capable of mimicking and reorganizing the extracellular matrix 
(ECM) to sustain damaged or pathological areas [202-206]. Besides, they can also favor tissue 
regeneration and healing processes [207-210]. The electrospinning process leads to final 3D 
structures with a high surface to volume ratio, composed of nanofibers and pores with 
variable sizes [211-215]. Electrospun scaffolds also have strong mechanical properties while 
maintaining a very low density [216, 217]. Moreover, their degradation profile can be 
predicted before being implanted in the human body or even modified later in situ [218, 219]. 
Thus, the implanted scaffolds slowly break down into non toxic fragments in the foreseen 
way, while the native tissue gradually grows replacing them [218, 219]. To date, many 
different synthetic and naturally derived polymers have been electrospun into nanofibers [220, 
221]. Among the most widely electrospun synthetic polymers there are the linear aliphatic 
polyesters polylactic acid [222-224], polyglycolic acid [225] and their copolymer, poly(lactic-
co-glycolic) acid (PLGA) [226-228]. All of these materials are biocompatible, can be easily 
obtained starting from cheap raw material sources [222-228], and have already been widely 
used in soft tissue regeneration [229, 230]. Although synthetic materials are strong, cheap and 
reliable, they unfortunately share no biochemical signatures and cannot interact with the 
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human body. This aspect can be sometimes highly desirable but in other cases a specific 
interaction with the target tissue is required. To obtain biomimetic nanofibers, an appealing 
approach has been the direct electrospinning of naturally derived polymers [231- 233]. To 
date, collagen, gelatin, fibrinogen, chitosan and alginate have all been used as starting 
polymers to obtain nanofibrous structures by electrospinning [233]. Many of these 
macromolecules retain cell-binding sites and biomolecular signatures that can favor cell-
material interactions [234]. The harvesting and processing of natural polymers, however, is 
not as straightforward as for synthetic ones, since their unique and specific properties are 
strongly influenced by temperature and solvent interaction, among others [234, 235]. Thus, a 
greater attention should be paid when working with them in order not to alter or even 
denaturate the starting polymer [235]. In the last years, growing attention has been paid to the 
advantages of hybrid scaffolds over single-component systems [197-202]. These structures 
can be obtained starting from solutions of mixtures of both synthetic and naturally derived 
polymers [197-199]. By blending two or more polymers together the final scaffolds can 
combine the characteristic properties of different polymers or even have new unique features 
[197-200]. While each single polymer unlikely shares the chemical composition and the 
structural properties of the native tissue, polymers used in combination can take mutual 
advantage, and better emulate the complexity of the ECM. Moreover, some (natural) polymers 
cannot be electrospun alone, while by blending them together with other materials they can be 
more easily solubilized and processed [236-238]. Not least, the direct production of blend 
scaffolds by electrospinning offers advantages over copolymerization and physical coating, 
alternative techniques employed to obtain hybrid structures [239-241]. Indeed, both processes 
require a generally irreversible chemical modification of the starting polymers, and are in 
most cases also solvent and material consuming [240, 241]. However, the development of 
well-blended hybrid scaffolds by electrospinning does not occur effortless due to the poor 
miscibility of the different polymers [242]. Badly blended polymeric nanofibers exhibit weak 
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mechanical strength, and have unpredictable material properties as a result of inhomogeneity 
[243]. Thus, the production of hybrid electrospun nanostructures that can profit from the 
favorable biological properties of the natural polymer (-s) and the mechanical of the synthetic 
one (-s) still remains a great challenge in tissue engineering and regenerative medicine. 
In this part of the thesis, we present the development and characterization of different hybrid 
electrospun (hyaluronic acid containing) scaffolds comprised of well-blended gelatin (GE) 
and poly-L-lactide (PLA), a natural and a synthetic polymer, respectively (Fig.21). Gelatin 
consists of a mixture of water-soluble protein fragments, with the same amino acid 
composition as collagen from which it is obtained through partial hydrolysis [244]. GE has 
already been successfully employed in the production of biomaterials profiting from its 
biodegradability, biocompatibility and commercial availability at low cost [245]. GE shows to 
have advantages over collagen, which include lower immunogenicity [246-248] and better 
solubility in aqueous systems [249]. Unmodified GE is also a good material to let cells adhere 
and proliferate, but has unfortunately low mechanical properties [250]. Not least, its high 
water solubility, representing an advantage by its processing, makes it necessary to cross-link 
GE before any use for biomedical applications. The cross-linking can strongly alter the 
material properties and its biocompatibility, even if, nowadays, different not destroying, clean 
methodologies are available [251-253]. To time, carbodiimide based cross-linking strategies 
represent the first choice [251-255]. Though being a limitation on one side, the cross-linking 
reaction offers, nevertheless, the possibility to (specific) bind other molecules to the amino 
acid residues in order to functionalize or modify GE [256-259]. GE can be obtained starting 
from different animal collagens [260-263]. The most commonly used forms in tissue 
engineering are derived from porcine [260, 261], fish [262] and bovine [263] tissues. Gelatin 
final properties depend not only on its source [260-263] but also on pH, temperature, and 
extraction time used for the collagen hydrolysis [264]. Depending on the processing 
conditions, GE with different molecular weight, Bloom strength and isoelectric point (IEP) 
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can be obtained [263, 265-269]. Collagen hydrolysis under acidic and alkaline conditions 
gives rise to type A GE (IEP at pH 8–9) and type B GE (IEP at pH 4–5), respectively [264, 
265]. Mammalian gelatin is rich in domains able to bind to cell-surface receptors and to other 
ECM proteins, such as fibronectin, thus offering an excellent substrate for attachment and 
proliferation of adherent cells [270]. In addition, gelatin can undergo collagenase mediated 
hydrolysis, which allows in vivo biologically driven remodeling of GE-based scaffolds [271] 
and, at the end, the material resorption without having any toxic residuals [272]. Cell adhesion 
for polylactide is instead sometimes not high, probably due to its hydrophobicity [273], but its 
mechanical strength and elasticity are much greater than GE [274, 275]. Thus, the 
combination of GE and PLA could provide composite materials with good cell adhesion and 
mechanical resistance as well. Polylactide is a widely used aliphatic polyester [276]. It can be 
chemically synthesized either by poly-condensation of lactic acid or by ring-opening 
polymerization of lactide, a cyclic dimer of lactic acid [277]. The preparation of polylactide 
fibers by electrospinning requires the use of high molecular weight polymers (~100kDa) 
[278]. Different configurations of the monomer units have a great influence on the thermal 
and mechanical properties of the polymer [112, 277]. For example, homopolymers produced 
from optically pure L,L- or D,D-lactide (PLLA or PDLA) have isotactic structure and are 
semi-crystalline with a glass-transition temperature (Tg) in the range of 55–60°C and a 
melting temperature (Tm) around 175°C [275]. The high Tm of isotactic PLLA and PDLA is of 
great importance when the thermal sterilization of the polymers is required, which is often the 
case in pharmacy, medicine and food industry [279, 280]. Polymerization of a racemic 
mixture of L- and D-lactic acid produces a copolymer (PDLLA), which is essentially atactic 
and amorphous. PDLLA has a Tg around 60°C but no Tm [275, 279]. PLLA has very good 
mechanical properties [281-285], while the amorphous PDLLA shows lower tensile strength 
and higher elongation at break compared to PLLA [275]. One of the very attractive properties 
of polylactide is that it can be resorbed in the human body after hydrolytic or enzymatic 
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digestion like many natural polymers, even if it is a synthetic one [286]. In vivo polylactide 
hydrolysis occurs by the cleavage of its ester bonds to give the non-toxic lactic acid which is 
finally eliminated as CO2 and H2O via Krebs cycle [287, 288]. Polylactide bioresorption is 
also influenced by its crystallinity degree [289]. It has been demonstrated that the in vivo 
hydrolysis of implants of high molecular weight PLLA requires a period of over a year, while 
their full resorption takes an even longer time [290, 291]. Amorphous PDLLA undergoes 
instead a faster complete bioresorption [292]. Thus, PLLA is the polymer of choice for the 
preparation of biomaterials when a longer exploitation time is required. 
Hyaluronic acid (HA) is a glycosaminoglycan (GAG) found within the ECM of human 
connective tissue consisting of the repetition of two alternating glycoside linkages of α-1, 4-
D-glucuronic acid and β-1, 3-N-acetyl-D-glucosamine (Fig.21) [293]. HA is involved in tissue 
repair, wound healing, and cellular adhesion and proliferation as well [294-297]. The unique 
viscoelastic and rheological properties together with its antibacterial and anti-inflammatory 
properties make HA an attractive material for biomedical applications [297]. In addition, HA 
has an essential role in the regenerative process for both the dermal and epidermal layers of 
the skin, and thus is considered of great potential as scaffold component to sustain healing 
processes [298]. In addition, various proteins that influence ECM interactions are able to bind 
to HA, and thus it can regulate how the cells will interact with the surrounding 
microenvironment [299, 300].  
 
Fig.21. Structure of the polymers used for the production of the hybrid electrospun scaffolds. 
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In this introduction, an overview is given about the many different chemical and biological 
properties of gelatin, polylactide and hyaluronic acid and about the advantages that can be 
achieved by blending them in ECM-like nanofibrous scaffolds. The ECM represents a 
complex structure whose composition and properties vary from tissue to tissue, and is 
responsible for cell proliferation, communication and differentiation [300]. We believe that 
polylactide and gelatin represent two completely different polymers that, however, share 
many similarities. For example, they are both bioresorbable and their mechanical properties 
strongly depend on the polymer molecular weight and how they are obtained and isolated, too. 
Thus, they offer a broad spectrum of possibilities and frontiers in the production of 
electrospun blend scaffolds for tissue engineering with unique features, depending on 
composition and ratio of the single components, and how they are processed (together). 
Finally, we also believe that HA, a GAG present in the ECM, and playing a key-role in its 
complex action, represents a good substrate to further functionalize hybrid GE/PLA 
electrospun scaffolds. Herein, we aimed to produce and characterize hybrid GE/PLA scaffolds 
with controlled wettability and hydrophobicity. These two purposes could be achieved by 
using blend electrospun scaffolds containing different GE:PLA w:w ratios (4:1, 5:2 and 1:1) 
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4.2.1. HYBRID GELATIN/POLY-L-LACTIDE SCAFFOLDS WITH CONTROLLED 
POROSITY AND WETTABILITY 
4.2.1.1. Production of the scaffolds by electrospinning and cross-linking 
For the production of the scaffolds, various electrospinning parameters were tested and those 
leading to a stable Taylor’s cone and jet, as well as to smooth and uniform fibers, were then 
used throughout the study. The conditions were first defined for pure PLA (chapter 2) and 
GE, and then adapted for the hybrid scaffolds. Generally, we noticed that when using a 
concentration higher than 10% w/v for GE the electrospinning process was not stable and the 
solution jellified at room temperature. Actually, when using the two highest GE:PLA ratios 
(4:1 and 5:2), the relative GE concentration was 10% w/v, which is the threshold value that, 
according to our observations, avoided its jellification during the electrospinning experiment. 
On the other side, when having PLA we noticed that a final polymer concentration higher than 
15% led to instable electrospinning processes with inhomogeneous final electrospun 
scaffolds. After the cross-linking, all the scaffolds shrank, but this effect was more evident 
when having a higher GE content. After having verified that no significant weight loss 
occurred for the pure PLA electrospun scaffolds when handling them according to the cross-
linking procedure used throughout this thesis, we were able to determine the final GE:PLA 
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4:1 9 18(±2):5 5.5±0.5 
5:2 9 9(±1):4 6.6±0.4 
1:1 9 9 (±1):10 8.0±0.2 
Table 2. Composition of Polymers expressed as ratio (w:w) and dimensions of the hybrid 
GE:PLA scaffolds, before and after cross-linking. 
The lower final GE content in the hybrid scaffolds is due to the cross-linking that leads to a 
water loss after intramolecular reaction between GE aspartic (L-Asp)/glutamic (L-Glu) acidic 
residues and the free amines of GE lysines (Fig.S10). Besides, a little GE solubilization could 
occur as well, due to water presence in the cross-linking solution. Nevertheless, this GE loss is 
not significant, and so we decided to always refer to the initial GE:PLA w:w ratio when 
characterizing the hybrid scaffolds, considering this value as the most reliable one.  
 
4.2.1.2. SEM and fiber diameter analysis 
All the electrospun scaffolds were characterized by SEM in order to assess the goodness of 
the electrospinning experiments (Fig.22 and Fig.23) and of the cross-linking reactions (Fig.22 
and Fig.24). Pure GE appeared good electrospun, showing a homogeneous random-oriented 
fiber distribution (Fig.22), with the fibers normally distributed around the mean value 
(Fig.22B, 334±35 nm). After the cross-linking, the porous-like structure of GE typical of 
electrospun scaffolds got lost, and no considerations about the fiber distribution could be done 
(Fig.22 C, D). 
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Fig. 22. A, B. SEM images at different magnifications of electrospun gelatin and fiber 
diameter distribution. C, D. SEM images at different magnifications of cross-linked 
electrospun GE. 
Blend electrospun scaffolds often lack of homogeneity, and the cross-linking reaction can 
instead strong alter their porous structure. Nevertheless, when blending GE together with PLA 
in different ratios (4:1, 5:2 and 1:1) we were able to generate scaffolds with a random fiber 
orientation. In all conditions, we obtained uniform fibers with no beads showing a normal 
distribution (Fig.23). When increasing the PLA content, the mean fiber diameter of the 
uncross-linked hybrid scaffolds significantly increased (GE:PLA 4:1, 243±25 nm versus 
GE:PLA 5:2, 344±22 nm, p=0.007; GE:PLA 4:1 versus GE:PLA 1:1, 420±38 nm, p=0.003; 
GE:PLA 5:2 versus GE:PLA 1:1, p=0.008, Fig.25) probably due to higher final polymer 
concentration and blend solution viscosity [197, 198]. 
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Fig. 23. A, B. SEM images at different magnifications of electrospun GE:PLA 4:1 scaffold 
and fiber diameter distribution.  C, D. SEM images at different magnifications of electrospun 
GE:PLA 5:2 scaffold and fiber diameter distribution. E, F. SEM images at different 
magnifications of electrospun GE:PLA 1:1 scaffold and fiber diameter distribution.   
After the cross-linking, the mean fiber diameter generally increased (Fig.24) but no significant 
differences could be found when comparing the values obtained for the same hybrid scaffolds 
before and after cross-linking, respectively (Fig.25). 
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Fig. 24. A, B. SEM images at different magnifications of electrospun GE:PLA 4:1 scaffold 
and fiber diameter distribution after cross-linking.  C, D. SEM images at different 
magnifications of electrospun GE:PLA 5:2 scaffold and fiber diameter distribution after cross-
linking. E, F. SEM images at different magnifications of electrospun GE:PLA 1:1 scaffold 
and fiber diameter distribution after cross-linking.   
However, a significant increase in the mean fiber diameter due to the increasing PLA content  
could still be detected when comparing the hybrid scaffolds among them, even after the cross-
linking (cross-linked GE:PLA 4:1, 297±25 nm versus cross-linked GE:PLA 5:2, 373±17 nm, 
p=0.007; cross-linked GE:PLA 4:1 versus cross-linked GE:PLA 1:1, 462±31 nm, p=0.003; 
cross-linked GE:PLA 5:2 versus cross-linked GE:PLA 1:1, p=0.009, Fig.25).   
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Fig.25. Fiber diameter comparison among the hybrid GE:PLA electrospun scaffolds before 
(blue) and after (red) cross-linking. 
 
4.2.1.3. Porosity, swelling properties and contact angle measurements 
According to the scaffold morphology (Fig.24) the cross-linked hybrid scaffolds having a 
higher GE content showed a higher porosity. This observation could be confirmed with 
DiameterJ analysis of the SEM images. According to this analysis, the mean pore size 
increased with the increasing PLA percentage (Fig.26A), while the number of pores 
(expressed as number of pores/ µm
2
, Fig.26B) decreased with the increasing PLA content. 
These microscopical properties of the hybrid cross-linked scaffolds correlated with the results 
obtained with the swelling test and the liquid displacement method to determine their 
wettability (Fig.26C) and porosity (Fig.26D), respectively. 
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Fig.26. Comparison of the properties of the cross-linked hybrid GE:PLA scaffolds. A. Pores 
mean size. B. Mean number of pores divided per the scaffold surface. C. Swelling properties.  
D. Porosity percentage according to the liquid displacement method.   
According to our observations, the scaffolds having a higher GE percentage and a greater 
number of pores retained more water (cross-linked GE:PLA 4:1, 507±15% versus cross-
linked GE:PLA 5:2, 362±34%, p=0.004; cross-linked GE:PLA 4:1 versus cross-linked 
GE:PLA 1:1, 121±9%, p=0.0008; cross-linked GE:PLA 5:2 versus cross-linked GE:PLA 1:1, 
p=0.004, Fig.26C). Besides, the higher GE percentage correlated with higher porosity as well 
(cross-linked GE:PLA 4:1, 71±3% versus cross-linked GE:PLA 5:2, 65±2%, p=0.003; cross-
linked GE:PLA 4:1 versus cross-linked GE:PLA 1:1, 58±4%, p=0.0019; cross-linked 
GE:PLA 4:1 versus cross-linked GE:PLA 5:2, p=0.024, Fig.26D). The scaffolds wettability 
was evaluated by measuring the contact angle too. Both 4:1 and 5:2 GE:PLA cross-linked 
scaffolds were highly hydrophilic, while the 1:1 GE:PLA blend was highly hydrophobic. The 
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obtained contact angle values were of 0° for the first two cross-linked scaffolds (4:1 and 5:2) 
and 129°±3° for the cross-linked 1:1 GE:PLA blend. 
 
4.2.1.4. Tensile tests 
The tensile strength and the E-modulus for pure PLA were already evaluated [88]. Besides, 
we investigated the same properties for hybrid GE:PLA and pure GE cross-linked scaffolds, 
before and after swelling (Fig.27). The swollen scaffolds showed a higher elongation at break 
when compared to the dry ones (Fig. 27 A-H), and our instrument was even not able to break 
down the wet hybrid samples (elongation (%) > 100%). However, no significant differences 
could be found in both Young’s modulus and tensile strength when comparing the same 
hybrid scaffolds, before and after swelling, respectively. Only pure cross-linked gelatin was 
significantly more elastic after swelling (dry cross-linked GE: 26.6±2.2 MPa versus swollen 
cross-linked GE: 1.22±0. 34 MPa). Thus, only the values obtained for the dry scaffolds were 
used for comparison and are reported. Interestingly, no significant differences in the ultimate 
tensile strength could be found when comparing the different cross-linked scaffolds among 
them (cross-linked GE, 2.5±0.4 MPa; cross-linked GE:PLA 4:1, 2.7±0.4 MPa; cross-linked 
GE:PLA 5:2, 2.2±0.5 MPa; cross-linked GE:PLA 1:1, 2.6±0.2 MPa, Fig.27I). In all cases, we 
were instead able to obtain hybrid scaffolds showing a significant lower Young’s modulus (E-
modulus) when compared to pure cross-linked GE (cross-linked GE:PLA 4:1, 16.4±2.4 MPa 
versus cross-linked GE, p=0.006; cross-linked GE:PLA 5:2, 13.0±2.4 MPa versus cross-
linked GE, p=0.004; cross-linked GE:PLA 1:1, 8.6±0.8 MPa  versus cross-linked GE, 
p=0.003, Fig.27J). Nevertheless, the scaffold showing the highest elasticity was that in 1:1 
GE:PLA ratio since it was significantly more elastic when compared to the other hybrid cross-
linked scaffolds (cross-linked GE:PLA 1:1 versus cross-linked GE:PLA 4:1, p=0.0016; cross-
linked GE:PLA 1:1 versus cross-linked GE:PLA 5:2, p=0.009, Fig.27J).  
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Fig.27. A-H. Representative stress-strain curves of: cross-linked hybrid GE:PLA 4:1 before 
(A) and after swelling (B); cross-linked hybrid GE:PLA 5:2 before (C) and after swelling (D); 
cross-linked hybrid GE:PLA 1:1 before (E) and after swelling (F); pure cross-linked GE 
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before (G) and after swelling (H). I, J. Comparison of Young’s modulus (I) and tensile 
strength (J) among the scaffolds in dry state. 
 
4.2.1.5. Raman spectra and principal component analysis (PCA)  
The different hybrid GE:PLA scaffolds were analyzed by Raman microspectroscopy, both 
before and after cross-linking. Raman analysis has the advantage of allowing the measurement 
of the unmodified samples in solid state without the need to pre-treat them, when compared 
for example to Fourier-transformed infrared spectroscopy (FTIR) [40, 43]. All the spectra are 
shown in Fig.28. According to the obtained spectra, the region of interest was found to be 
between 740 and 920 cm
-1
. In particular, the signals at 743 cm
-1
 (Fig.28, green arrow) and at 
876 cm
-1
 (Fig. 28, red arrow) were attributed to vibrations of the free carboxylic groups of L-
Glu [301, 302] and L-Asp [301, 303], respectively. Both signals could be found only in the 
spectra of the uncross-linked GE containing scaffolds. After the cross-linking both signals 
disappear, since L-Glu and L-Asp are involved in the formation of new amide bonds after the 
reaction [251-253]. The signal at ca. 895 cm
-1
 (Fig. 28, blue arrow) was instead assigned to 
the C-COO stretching [304-306] of the polyester PLA, and so used to identify the increasing 
PLA content in the hybrid scaffolds. Moreover, after the cross-linking, this signal appears 
more narrow and with a higher relative intensity, reflecting the higher final PLA content in the 
scaffolds after the cross-linking. 
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Fig.28. Raman spectra of different hybrid electrospun scaffolds. Starting from the top: cross-
linked 1:1 GE:PLA; uncross-linked 1:1 GE:PLA; cross-linked 5:2 GE:PLA; uncross-linked 
5:2 GE:PLA; cross-linked 4:1 GE:PLA; uncross-linked 4:1 GE:PLA. 
The principal component analysis (PCA) was performed as well to compare the obtained 
spectra and detect differences in the samples. This analysis allows distinguishing samples 
with significant differences in the contribution of single peaks to the final spectrum. Herein, it 
allowed us to group the different samples, and to detect spectral differences due to the cross-
linking and the increasing PLA content in the samples as well. Actually, we were able to 
detect the effect of the cross-linking for each single hybrid scaffold (Fig.29 A-C), separating 




 and 895 cm
-1
 
which represent the peaks of interest as already observed in the Raman spectra (Fig.28). 
Besides, the PCA analysis allowed us to group and distinguish the different hybrid scaffolds 





 and 895 cm
-1
 (Fig. 29D).  
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Fig.29. PCA analysis of the RAMAN spectra of: GE:PLA 4:1 with the relative PCs (A); 
GE:PLA 5:2 with the relative PCs (B); GE:PLA 1:1 with the relative PCs (C); all the hybrid 
GE:PLA scaffolds (XL=after cross-linking) with the relative PCs (D).  
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4.2.1.6. Scaffolds biocompatibility 
The biocompatibility of all cross-linked hybrid GE:PLA scaffolds containing different ratios 
of the two polymers was verified performing a cell proliferation assay (Fig.30).  
 
Fig.30. Results of the MTS assay for all the hybrid cross-linked scaffolds, as well as for pure 
cross-linked GE. 
According to the results of the MTS assay all the scaffolds showed a high biocompatibility, 
since their extracts after 72 hours incubation didn’t exhibit any cytotoxic effect towards 
HDFs. The test was performed also for the pure cross-linked GE. Biocompatibility of pure 
PLA was previously verified [88]. According to the results neither the cross-linking reaction 
nor the polymers have cytotoxic effects on HDFs. 
 
4.2.2. HYBRID GELATIN/POLY-L-LACTIDE IN 1:1 RATIO SCAFFOLDS WITH 
CONTROLLED HYDROPHOBICITY  
4.2.2.1. Functionalization of the scaffolds with hyaluronic acid 
Cross-linking of the scaffolds was performed in presence of HA or not. The hybrid GE:PLA 
1:1 electrospun scaffold was in this case chosen because it showed greater elasticity in 
comparison with the other hybrid scaffolds after cross-linking. Moreover, it was the only 
hydrophobic scaffold (section 4.2.1.3.). Therefore, the HA functionalization could also help to 
increase scaffold hydrophilicity and, thus, to enhance cell adhesion [307, 308]. The highest 
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HA concentration in the cross-linking solution was 0.03% w/v, since when going over this 
value we were not able anymore to solubilize HA which instead jellified in the reaction 
mixture. Besides, a simple HA coating was performed as well, using the same experimental 
conditions, but not having any cross-linking reagent in the HA containing solution. In this 
case, only one HA concentration was used (0.025% w/v).  
 
4.2.2.2. SEM and fiber diameter analysis 
All the electrospun scaffolds were characterized by SEM in order to investigate the 
morphology of the electrospun scaffolds after the cross-linking or after the coating in presence 
of HA (Fig.31). The scaffolds which did not contain HA (GE:PLA 1:1, before and after cross-
linking) were previously characterized (section 4.2.1.2.). When the hybrid GE:PLA 1:1 
scaffold was cross-linked in presence of HA, we were still able to obtain scaffolds with a 
random oriented fiber distribution. Moreover, the mean fiber diameter did not significantly 
change when compared to the cross-linked hybrid GE:PLA 1:1 scaffold (p>0.7 in all cases), 
and we could still obtain a normal diameter distribution (Fig.31). Nevertheless, when using 
the highest HA concentration (0.03% w/v) the initial fibrous structure of the scaffold appeared 
altered (Fig.31G, H), probably due to a not complete HA solubilization in the cross-linking 
solution. Therefore, we decided to not further characterize the scaffold cross-linked in 
presence of the highest HA concentration, since by losing the initial structure it is not more 
possible to profit from the advantages of the electrospinning technique by processing the 
polymer(-s). Finally, when analyzing the hybrid GE:PLA 1:1 cross-linked scaffold after 
having coated it with HA, the fibrous structure did not appear homogeneous. Instead, a HA 
film formed on the scaffold surface and no normal diameter distribution could be found 
(Fig.31 I, J).  
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Fig. 31. A, C. SEM images at different magnifications of HA containing electrospun GE:PLA 
1:1 blend scaffolds and fiber diameter distribution.  A, B. SEM images at different 
magnifications of electrospun GE:PLA 1:1 cross-linked in presence of 0.015% w/v HA and 
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fiber diameter distribution. C, D. SEM images at different magnifications of electrospun 
GE:PLA 1:1 cross-linked in presence of 0.02% w/v HA and fiber diameter distribution. E, F. 
SEM images at different magnifications of electrospun GE:PLA 1:1 cross-linked in presence 
of 0.025% w/v HA and fiber diameter distribution. G, H. SEM images at different 
magnifications of electrospun GE:PLA 1:1 cross-linked in presence of 0.03% w/v HA and 
fiber diameter distribution. I, J. SEM images at different magnifications of electrospun cross-
linked GE:PLA 1:1 coated in presence of 0.025% w/v HA and fiber diameter distribution. 
 
4.2.2.3. Porosity, swelling properties and contact angle measurements 
The porosity and the wettability of the HA containing hybrid GE:PLA scaffolds were not 
significantly different (data not shown) from the values obtained for the cross-linked GE:PLA 
1:1 scaffold (section 4.2.1.3). Scaffold hydrophilicity instead increased when the hybrid 
GE:PLA 1:1 scaffolds were cross-linked or coated in presence of HA (Fig.32). Generally, all 
the HA containing scaffolds were significantly more hydrophilic than the pure cross-linked 
GE:PLA 1:1 scaffold not containing HA (no HA) which was highly hydrophobic (Fig.32G. no 
HA: 129°±3° versus 0.015%HA: 87±10 ° , p=3e
-7
; no HA versus 0.02%HA: 68±11°, p=7e
-9
; 
no HA versus 0.025%HA: 53±9°, p=4e
-9
; no HA versus HA coated: 36±3°, p=2e
-10
). The 
increasing HA concentration also led to a signicantly higher scaffold hydrophilicity (Fig.32G. 
0.015%HA versus 0.02%HA, p=0.032; 0.015%HA versus 0.025%HA, p=0.004; 0.02%HA 
versus 0.025%HA, p=0.027). Besides, when washing the HA coated scaffold according to the 
normal experimental procedure (described in section 1.5), the cross-linked GE:PLA 1:1 
scaffold regained the initial hydrophobicity. Indeed, the contact angle was not significantly 
different if compared to the uncoated scaffold (HA coated (post washing): 126±3° versus no 
HA, p=0.21). Thus, the chemical cross-linking of HA seems to show advantages compared to 
a simple coating, since if performing biological tests, scaffolds are usually incubated together 
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with cells in culture medium for at least 24 hours. As a result, the HA film deposited on the 
electrospun fibers after the coating may be washed away. 
 
Fig. 32. A-F. Frames of the contact angle evaluation of the hybrid GE:PLA scaffolds cross-
linked in presence of 0.00% w/v HA (A), 0.015% w/v HA (B), 0.02% w/v HA (C), 0.025% 
w/v HA (D), coated with HA (E) and coated with HA after standard washing procedure (F). 
G. Statistical comparison of the average contact angles for the different hybrid GE:PLA 1:1 
scaffolds.  
 
4.2.2.4. Tensile tests 
The mechanical properties of the different hybrid GE:PLA 1:1 scaffolds were analyzed. 
Representative stress-strain curves for the hybrid GE:PLA scaffolds cross-linked or coated in 
presence of specific HA amounts, before or after swelling, are shown in Fig.33A-H. No 
significant differences could be detected regarding the tensile strength (Fig.33I) and the 
Young’s modulus (Fig.33J) when comparing the cross-linked scaffolds among them, as well 
as in comparison to the hybrid GE:PLA 1:1 scaffold cross-linked without HA, previously 
characterized in section 4.2.1.4. (Fig.27).  
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Fig.33. A-D. Representative stress-strain curves of hybrid GE:PLA 1:1 scaffolds cross-linked 
in presence of 0.015% w/v HA (A), 0.02% w/v HA (B), 0.025% w/v HA (C), or coated with 
HA (D). E-H. Representative stress-strain curves after swelling of hybrid GE:PLA 1:1 
scaffolds cross-linked in presence of 0.015% w/v HA (E), 0.02% w/v HA (F), 0.025% w/v 
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HA (G), or coated with HA (H). I. Comparison of the tensile strength among the HA 
containing cross-linked GE:PLA 1:1 scaffolds. J. Comparison of the Young’s modulus among 
the HA containing cross-linked GE:PLA 1:1 scaffolds.  
Furthermore, when comparing the swollen and dry HA containing scaffolds among them no 
significant changes in both Young’s modulus and tensile strength could be found (data not 
shown). However, all the swollen scaffolds showed a greater elongation at break than the dry 
samples. According to our results, the addition of HA does not affect the mechanical 
properties of the hybrid GE:PLA 1:1 cross-linked scaffold, differently from literature data by 
Yang et al. working on silk fibroin [33]. 
 
4.2.2.5. Raman spectra and principal component analysis (PCA) 
Raman microspectroscopy was used to investigate HA presence in the scaffolds. The only two 
signals in the Raman spectrum of the pure HA, in powder, (Fig.34, first spectrum from the 
top) that do not appear in the Raman spectrum of GE:PLA 1:1 scaffold (Fig.28), are those 
related to vibrations of the β-linkages of the polysaccharide and skeletal C-O-C stretchings, 
which have a Raman shift of 900cm
-1
 (Fig.34 first spectrum from the top, blue arrow) and 
945cm
-1
 (Fig.34 first spectrum from the top, red arrow), respectively [309]. In the HA coated 
scaffold the signal related to the C-O-C stretchings appears to be shifted to a lower 
wavenumber of 897 cm
-1 
(Fig.34 first spectrum from the bottom, red arrow), probably due to 
the interaction of HA with the scaffold. The signal related to the stretching of the β- 
glucuronidic linkages which is significant for the maintaining of the glycoside structure [309] 
appears instead not shifted (Fig.34 first spectrum from the bottom, blue arrow). The same 
signals found in the Raman spectrum of the HA coated scaffold could be found in the hybrid 
GE:PLA 1:1 scaffold cross-linked in presence of 0.025% w/v HA (Fig.34 second spectrum 
from the top, blue and red arrows). When using lower HA concentrations only the signal 
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related to skeletal C-O-C linkage stretching could be detected (Fig.34 third and fourth 
spectrum from the top, red arrow). Finally, after washing the HA coated cross-linked scaffolds 
both signals significant for the HA presence could not be detected anymore, confirming our 
hypothesis that the HA deposited film is washed away. 
 
Fig.34. Raman spectra. Starting from the top: HA as powder; GE:PLA 1:1 scaffold cross-
linked in presence of 0.025% w/v HA; GE:PLA 1:1 scaffold cross-linked in presence of 
0.02% w/v HA; GE:PLA 1:1 scaffold cross-linked in presence of 0.015% w/v HA; HA coated 
cross-linked GE:PLA 1:1 scaffold after standard washing procedure; HA coated cross-linked 
GE:PLA 1:1 scaffold. 
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Besides, we also performed a PCA analysis comparing the scaffolds cross-linked in presence 
of HA among them (Fig.35A), and, separately, the coated one, before and after washing 
(Fig.35B). In all cases the hybrid GE:PLA 1:1 scaffold cross-linked without HA (no HA), 
previously characterized in section 4.2.1.5., was used as a control.  
 
Fig.35. PCA analysis with the relative PCs of the Raman spectra of: A. hybrid GE:PLA 1:1 
scaffold cross-linked either in presence of different HA w/v% (+0.015% HA; +0.02% HA; 
+0.025% HA) or without HA (no HA); B. hybrid cross-linked GE:PLA 1:1 scaffold before 
(no HA), after HA coating (HA coated) and after HA coating followed by washing (HA 
coated (post washing)).  
According to the PCA analysis we could detect the increasing HA content in the cross-linked 
scaffolds, mainly taking into account the contribution of the signal at 897 cm
-1
 to the final 
spectra (Fig.35A). On the other side, the PCA analysis allowed us to distinguish the HA 
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coated scaffold from the starting hybrid cross-linked GE:PLA scaffold, while after the 
washing procedure the coated scaffold was similar to the uncoated (Fig.35B). These results 
confirm the advantages of using the cross-linking procedure instead of a simple coating when 
aiming to obtain HA containing scaffolds for in vitro cell-culture.  
 
4.2.2.6. Scaffolds biocompatibility 
The biocompatibility of all cross-linked hybrid GE:PLA 1:1 scaffolds containing HA was 
verified performing a cell proliferation assay (Fig.36).  
 
Fig.36. Results of the MTS assay for all the hybrid HA containing cross-linked GE:PLA 1:1 
scaffolds. 
According to the results of the MTS assay all the scaffolds showed a high biocompatibility, 
since the scaffold extracts after 72 hours incubation did not show any cytotoxic effect towards 
HDFs. These results suggest that neither the cross-linking reaction nor the presence of HA 
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4.2.3. MPM AND FLIM ANALYSIS OF HDFs ON HYBRID GELATIN/POLY-L-
LACTIDE SCAFFOLDS 
4.2.3.1 MPM imaging 
In the last part of the work, we verified cellular adhesion and cellular growth properties of 
human dermal fibroblasts (HDFs) on the different hybrid electrospun scaffolds using 
multiphoton microscopy (MPM) which represents a not invasive, marker-free methodology 
[94-97]. All the cross-linked hybrid GE:PLA scaffolds with a different ratio between the two 
polymers, as well as the GE:PLA 1:1 hybrid scaffold cross-linked in presence of 0.025% w/v 
HA were investigated. Gelatin is reported to exhibit autofluorescence at an excitation 
wavelength of 355 nm [310], and in our case we could detect this autofluorescence signal 
(Fig.37A-H) using a two-photon excitation at a wavelength of 710 nm. However, we were 
also able to image HDFs within the scaffolds by inducing NAD(P)H autofluorescence at the 
same wavelength (Fig.37 A-H). For easier cellular visualization also a control represented by 
HDFs seeded on glass is shown in Fig.37I and Fig.37J. Furthermore, images where HDFs are 
labeled with yellow arrows (Fig.37 B, D, F, H, J) are reported.  
 
Fig.37. A-J. MPM images of HDFs seeded on hybrid GE:PLA scaffolds (A,B. 4:1; C,D. 5:2; 
E,F. 1:1; G,H. 1:1 + 0.025% w/v HA) or on glass (I,J). Scale bar equals 40µm.  
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Interestingly, we were able to image both cells and scaffolds at the same time using MPM, 
showing that HDFs adhere not only on the scaffold surface but mainly within the fibrous 
structure which is a must when aiming to produce a 3D in vitro model. According to 
morphological observations, the hybrid cross-linked GE:PLA 5:2 scaffold seems to be the one 
where more HDFs adhered and proliferated (Fig.37 C, D). However, cells could be imaged in 
all the other hybrid GE:PLA scaffolds as well (Fig.37 A,B, E-H), showing proliferation and  
adhesion properties similar to those of HDFs seeded on glass (Fig.I, J) according to 
morphological observations. 
 
4.2.3.2 FLIM analysis 
After MPM imaging of HDFs within the fibrous hybrid GE:PLA scaffolds we investigated the 
same samples using fluorescence lifetime imaging microscopy (FLIM, Fig.38), which allows 
the analysis of the metabolism of the target cells, parallel to their imaging, having NAD(P)H 
as a target [42]. Interestingly, even if having a strong autofluorescence from the gelatin, using 
a biexponential decay curve fitting, we were able to distinguish the cells from the scaffolds by 
a false colour coding, based on a 2D-correlation. As a matter of fact, the cells show a much 
shorter τ1 than the scaffolds, due to the free NAD(P)H fluorescence lifetime [42]. This value 
also leads to a shorter mean fluorescence lifetime (τm) which directly depends on the τ1 values 
[29]. We believe that a discrimination between cells and scaffolds using two variables could 
be an interesting way to separate the single contributions, and thus analyze the cells alone. 
Actually, when having cells within the fibrous scaffolds (Fig.38 A-L) they could be coulored 
in yellow/light green (Fig.38 B, E, H, K) due to shorter τ1 and τm values when compared to the 
scaffold fibers which were instead coloured in blue due to longer τ1s and τms (Fig.38 B, E, H, 
K).  
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Fig.38. FLIM analysis of HDFs seeded on hybrid GE:PLA scaffolds (A-L) or on glass (M-O). 
Scale bar equals 25µm.  
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Looking at the 2D-correlation having τ1 and τm as variables on the x and y axes, respectively 
(Fig.38 C, F, I, J), the pixels obtained from the cells lay in the south-west part of the plot, 
while those due to scaffold contribution in the north-east one. To confirm our hypothesis, 
when analyzing HDFs on glass (CTRL, Fig.38 M-O), all the values lay in the south-west part 
of the plot, with more than the 95% of the points having τ1<1000ps and τm<1750ps (Fig.38O). 
According to these observations we developed a spreadsheet using Microsoft Excel™ that 
allowed us to isolate all the pixels satisfying at the same time these two conditions (τ1<1000ps 
and τm<1750ps) in the FLIM images. Once isolated these pixels, we could compare the α1 (%) 
values for the HDFs, to evaluate the relative glycolysis/oxidative phosphorylation 
contribution to their metabolism (Fig.39). According to the results, only the cells in the hybrid 
scaffold having the highest GE content showed a lower glycolytic activity when compared to 
HDFs seeded on glass (α1 (%) 4:1= 54±8% versus CTRL α1 (%) = 73±6%). No significant 
differences could be instead found when comparing the other cross-linked hybrid GE:PLA 
scaffolds with the control (CTRL), or when comparing the different GE:PLA scaffolds among 
them (Fig.39).  
 
Fig.39. Comparison of the α1 (%) values for HDFs seeded on different hybrid GE:PLA 
scaffolds. Results arise from a biexponential fitting of the FLIM data.  
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Blend electrospun nanofibrous scaffolds are of growing interest as biomimetic structures with 
unique properties resulting from the combination of naturally derived and synthetic polymers 
[197, 198]. In this thesis, different hybrid GE/PLA electrospun scaffolds were produced and 
characterized with the final aim of obtaining biomimetic porous structures with tunable 
physical and mechanical properties. To time, some attempts have already been made to 
produce well-blended GE/PLA scaffolds [311-315]. The best electrospun hybrid scaffolds 
composed of GE and PLA have been so far obtained using HFIP as solvent for polymers 
processing [312, 313, 315]. Thus, throughout this thesis we used HFIP, since it ensured us to 
dissolve both GE and PLA, either alone or together (in different ratios too), and to process the 
resulting blend solutions by electrospinning. In the first part, hybrid GE/PLA scaffolds having 
different relative polymers ratios were characterized. Three different GE:PLA w:w ratios (4:1, 
5:2 and 1:1) were chosen for scaffolds production, characterization and comparison. All the 
scaffolds were homogeneous, even after cross-linking, showing a high porous structure with 
random oriented fibers, according to the SEM analysis. In all cases, the mean fiber diameter 
was in the hundred nanometers scale, but this value generally increased with the increasing 
PLA percentage. These results are in agreement with the data by Moon et al. [311] and Wang 
et al. [314]. A different behavior could be instead found by Kim et al. [313]. However, Kim et 
al. [313] used 2,2,2-trifluoroethanol as solvent for the electrospinning experiments, while in 
this work HFIP was employed like Moon et al. [311] and Wang et al. [314]. The chosen 
solvent plays an important role for polymers processing which reflects on the final 
morphology of the electrospun scaffolds [100, 316, 317]. The hybrid scaffolds with the 
highest GE content showed a greater porosity, due to a higher number of pores, even with a 
lower mean size. These results agree with previous studies [318-320]. Moreover, we could 
also infer that, the higher the porosity is the more water is retained by the cross-linked hybrid 
scaffolds. These swelling properties are also directly related to the GE content [321, 322]. It is 
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well known that hydrogels and foam or sponge scaffolds have a higher porosity than the 
electrospun ones [323]. However, electrospinning allows the production of fibrous 3D nano-
structures which better mimic the ECM, still remaining highly porous [202]. Not least, we 
also demonstrated that by blending GE and PLA, we could obtain final cross-linked scaffolds 
with improved elasticity if compared to pure cross-linked GE, due to the lower Young’s 
modulus shown in the dry state. According to these results, we also belive that the stiffness of 
hybrid GE/PLA scaffolds could be tuned. However, pure cross-linked GE Young’s modulus 
may represent a threshold value when aiming to increase scaffold stiffness. It has already been 
proved that mechanical properties of electrospun cross-linked GE strongly change after water 
uptake [324], even when blended together with other polymers [324-327]. As already 
observed by Kharaziha et al. [324] we could find a higher elasticity and a better elongation at 
break for pure cross-linked GE after swelling when compared to the dry scaffolds. However, 
in our case, when blending GE together with PLA the elastic modulus of the wet samples was 
not significant different from the values obtained for the dry scaffolds. A similar behavior 
could be found by Jing et al. when blending GE together with poly (propylene carbonate) 
[327]. Nevertheless, as previously shown [324, 326, 327] all the scaffolds showed a much 
greater elongation at break after swelling (elongation (%) > 100%), and our instrument was 
even not able to break down the scaffolds. Moreover, changes in the Raman spectra of the 
hybrid scaffolds due to the cross-linking reaction were found, suggesting a new non-
destructive approach to detect the effectiveness of this reaction. Finally, all the different 
hybrid scaffolds showed a high biocompatibility towards HDFs according to the results of the 
MTS cell proliferation assay. The MTS assay results prove that no toxic reagents or solvent 
residuals remain in the scaffolds after the whole processing ranging from electrospinning to 
cross-linking.  
In the second part of the work described in this chapter, hybrid GE:PLA 1:1 scaffolds cross-
linked in presence of different HA concentrations according to the method described by Yang 
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et al. [33] were produced and characterized. In this case, the final aim was to obtain hybrid 
scaffolds with a tunable, enhanced hydrophilicity. It is well known that surface hydrophilicity 
of 3D electrospun scaffolds better favor cell attachment and proliferation [307-308, 328-332]. 
Besides, we could also introduce HA, an essential component of the ECM, involved in many 
biological or physiological functions [333-335]. Many different attempts have already been 
made to produce HA containing electrospun scaffolds [336-340]. To time, the best results in 
directly electrospinning HA have been achieved either using NH4OH/DMF as solvent for its 
processing [338, 339] or using the thiolated HA as starting substrate [340]. However, the 
usage of a strong basic system as well as of chemically modified HA have been questioned 
since the final HA properties may be altered [341]. Considering these literature data, in this 
thesis, we decided to bind HA to previously electrospun hybrid GE:PLA scaffolds using the 
procedure recently described by Yang et al. [33]. The cross-linking chemistry used by Yang et 
al. is based on the simultaneous use of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDC) and N-hydroxysuccinimide (NHS), which is a widely exploited and well-approved 
approach [33, 253-256]. According to this procedure, HA is firstly bound to electrospun 
scaffolds when cross-linking them (Fig.S10). Cross-linking is a necessary step when working 
with water-sensitive polymers like gelatin, and thus it doesn’t represent a further step in the 
scaffolds production. Firstly, we investigated the structure of the scaffolds using SEM. We 
could notice, that the addition of HA didn’t affect the fiber diameter distribution of the 
electrospun scaffolds, still having a normal distribution with an average diameter of ca. 500 
nm. However, when increasing the HA concentration to 0.03% w/v the fibrous structure of the 
final scaffold was altered and different from the one typical of good electrospun scaffolds. 
According to these observations and the chosen methodology [33], we believe that the 
0.025% w/v concentration represents a threshold value when aiming to cross-link HA to 
hybrid GE:PLA scaffolds in 1:1 ratio, and still obtain ECM-like final structures. To prove that 
the hydrophobicity of the hybrid cross-linked GE:PLA blend could be reduced by increasing 
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the HA percentage, the contact angle of all the different scaffolds was measured. As already 
observed by Yang et al. [33], the scaffolds became the more hydrophilic the higher was the 
HA concentration used by the cross-linking reaction. Moreover, we could also demonstrate 
that the addition of HA did not modify the mechanical properties of the hybrid GE/PLA 
scaffold. Besides, we showed the advantages offered by the chemical cross-linking of HA to 
the hybrid electrospun scaffolds over a simple HA coating of the materials. According to our 
observations the HA film deposited on the cross-linked hybrid scaffolds due to the coating is 
washed away from the materials after 24 hours incubation in an aqueous environment. Thus, 
this kind of functionalization is not useful for the most biological tests [41, 160, 317]. The 
biocompatibility of all the scaffolds was verified too by a cell proliferation test in order to 
prove that no toxic reagents and solvents were retained in the scaffolds after their 
modification. To check the HA presence in the hybrid electrospun scaffolds Raman analysis 
was performed. This technique allowed us to detect the increasing HA content in the 
electrospun scaffolds even if the peaks used for HA detection were shifted in the spectra of 
the hybrid GE/PLA functionalized materials. These findings suggest, that this analysis allows 
the HA detection also in electrospun scaffolds as previously demonstrated [342]. However, 
the detection of HA in so low percentages may be confirmed with more sensitive and specific 
analyses [343-345]. In the last part of this work, the proliferation of HDFs on the hybrid 
cross-linked scaffolds could be imaged and analyzed using MPM coupled with FLIM. 
According to our results it is also possible to distinguish the specific cellular NAD(P)H 
contribution to the final fluorescence lifetime, even if a strong autofluorescence was detected 
from the scaffold fibers during the FLIM analysis. This separation could allow analysis of 
cellular metabolism of HDFs besides their imaging even in a complex matrix using an 
innovative, non-invasive approach. Nevertheless, cell proliferation on the hybrid scaffolds and 
the cell-material interactions have to be investigated using already established methodologies 
[330, 331, 346, 347].  
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In this part of the thesis, different hybrid GE/PLA electrospun scaffolds were produced and 
characterized. By changing the ratio between the two polymers we were able to obtain 
scaffolds with different porosities, which directly correlate with their swelling properties. In 
particular, the porosity and the swelling properties of the scaffolds increased when using a 
higher GE content. Besides, we were also able to obtain hybrid GE/PLA electrospun scaffolds 
whose hydrophilicity could be enhanced by introducing increasing amounts of HA. In all 
cases, we were able to characterize the scaffolds with Raman microspectroscopy which is a 
non-destructive, non-invasive methodology when compared to FTIR. Moreover, all the 
scaffolds showed no cytotoxic effects towards HDFs. Afterwards, cell adhesion in the 
different scaffolds could be imaged and analyzed by MPM coupled with FLIM without any 
staining. On resuming, we were able to tune the properties of hybrid GE/PLA electrospun 
scaffolds without changing the nature of used polymers, and to characterize them in a non-
destructive, marker-free way. Both aspects are of great interest when aiming to develop new 
versatile in vitro models that could be potentially used for in vivo applications.  
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SUMMARY AND CONCLUDING REMARKS 
 
In the first part of the thesis (chapters 2 and 3), pure poly-L-lactide (PLA) scaffolds were 
obtained and characterized as delivery systems for Diclofenac sodium salt (DCF) and a 
synthetically obtained prodrug of it for the treatment of actinic keratosis. The effective drug 
encapsulation, as well as the release could be demonstrated in all cases. When working with 
the unmodified DCF we were also able to control the release profile by adding small amounts 
of dimethyl sulfoxide. The DCF-loaded scaffold was used as a delivery system to induce in 
vitro cell death in human fibroblasts. The target cells were observed using MPM coupled with 
fluorescence lifetime imaging microscopy (FLIM), using a non-invasive, marker-free in vitro 
model to investigate drug effects. The Diclofenac prodrug was obtained via solid phase using 
a versatile, clean, high yielding procedure. Besides, as a novelty, the drug encapsulation and 
its release from the scaffold could be imaged using multiphoton microscopy (MPM). 
Moreover, the synthesized DCF prodrug showed no cytotoxic effects towards human dermal 
fibroblasts when compared to the unmodified DCF. Thus, we believe that DCF-Gly could be 
an interesting DCF precursor for the treatment of actinic keratosis and other diseases. In the 
last part of the thesis (chapter 4), we produced and characterized different hybrid gelatin/PLA 
scaffolds. In this case, the goal was to obtain well-blended scaffolds with tunable properties, 
such as porosity, stiffness, hydrophobicity and wettability. This aspect is of great interest 
since one of the main problems in tissue engineering is the difficulty of reproducing in vitro 
properties that in vivo usually differ from tissue to tissue. We were instead able to control 
them even without changing the employed polymers, by simply modifying few experimental 
processing conditions. Not least, the hybrid scaffolds were spectroscopically characterized 
with Raman microspectroscopy, while cellular interaction was analyzed with MPM coupled 
with FLIM, with all of them being non-invasive, non-destructive and marker-free approaches.  
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SUPPLEMENTARY MATERIALS  
 
Fig.S1A. RP-HPLC chromatogram of DCF 1mg/mL in PBS. 
 
Fig.S1B. RP-HPLC chromatogram of DCF in PBS after its release from a PLA scaffold. 
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Fig.S1C. RP-HPLC chromatogram of DCF in PBS after its release from a DMSO containing 
PLA scaffold. 
 
Fig.S2A. Full EDX spectrum of a PLA scaffold electrospun using DMSO as a co-solvent.  
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Fig.S2B. Full EDX spectrum of a DCF-loaded PLA electrospun scaffold.  
 
Fig.S2C. Full EDX spectrum of a DCF-loaded PLA scaffold electrospun using DMSO as a 
co-solvent.  
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Fig.S2D. Full EDX spectrum of a PLA scaffold electrospun using DMSO as a co-solvent after 
24h PBS immersion and washing.  
 
Fig.S2E. Full EDX spectrum of a DCF-loaded PLA electrospun scaffold after 24h PBS 
immersion and washing.  
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Fig.S2F. Full EDX spectrum of a DCF-loaded PLA scaffold electrospun using DMSO as a 
co-solvent after 24h PBS immersion and washing. 
 
Fig.S3. SEM images of un-coated scaffolds acquired before making EDX analysis on the 
samples. A. Images of PLA + DCF (w DMSO) acquired using a voltage of 4 kV. B. Images of 
PLA + DCF (w DMSO) acquired using a voltage of 10 kV. Scale bar equals 10 µm. 
 
Fig.S4. Results of the MTS cell proliferation assay for PLA electrospun scaffolds containing 
DCF and/or DMSO. 
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Fig.S5. FLIM results of the control samples. HDFs (control, CTRL) versus HDFs in presence 
of a PLA scaffold (CTRL+PLA); treated HDFs in presence of DCF-loaded PLA scaffold 





H-NMR of DCF-Gly in DMSO-d6. 
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Fig.S6C. MS-MALDI spectrum of DCF-Gly. 
 
Fig.S7. MPM image of pure electrospun PLA (scale bar: 10µm, excitation wavelength:710 
nm, laser power: 3.2 mW, acquisition time: 26s). 
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Fig.S8A. RP-HPLC chromatogram of DCF-Gly 1mg/mL in PBS. 
 
Fig.S8B. RP-HPLC chromatogram of DCF-Gly in PBS after its release from a PLA scaffold. 
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Fig.S9. FLIM analysis using a biexponential decay of τ1 (A) and τ2 (B) of HDFs seeded on 
glass (NC) alone or incubated together with different electrospun scaffolds. 
 
Fig.S10. Reaction scheme for the EDC/NHS-based cross-linking. First, EDC reacts with 
carboxylic acid groups (from HA glucuronic acid or from GE L-Asp and L-Glu) to form an 
active O-acylisourea intermediate. Addition of NHS to EDC reactions increases efficiency 
and enables molecule that is easily displaced by nucleophilic attack from primary amino 
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